Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of the TGF-beta family and uses thereof
Patent Information
- Application Number
- JP2023527452
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-15
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-08
AI Technical Summary
Current treatments for conditions associated with elevated TGF-β and activin signaling, such as cancer and fibrosis, are inadequate as they primarily target TGF-β alone, neglecting the parallel overexpression of activin, which contributes to immune suppression and fibrosis progression.
Development of novel polypeptide-based multispecific antagonists that simultaneously inhibit both TGF-β and activin signaling, utilizing antigen-binding molecules to target both ligands, including antibodies and receptor extracellular domains, to restore immune surveillance and attenuate fibrosis.
The multispecific antagonists effectively neutralize both TGF-β and activin, enhancing immune response against cancer cells and reducing fibrosis by inhibiting Smad2/3 signaling, thereby improving treatment outcomes for various diseases.
Abstract
Description
[Technical Field]
[0001] Related patent applications This application claims the interests of U.S. Provisional Application No. 63 / 113,920, filed on 15 November 2020, and U.S. Provisional Application No. 63 / 109,814, filed on 4 November 2020, each of which is incorporated herein by reference in whole. [Background technology]
[0002] Background technology The transforming growth factor beta (TGF-β) superfamily consists of TGF-β protein, activin, growth and differentiation factor (GDF), bone morphogenetic protein (BMP), glial-derived neurotrophic factor (GDNF), inhibin, Nodal, Lefty, and Müllerian duct inhibitor (MIS). Ligands of the TGF-β superfamily form dimers that bind to heterodimeric receptor complexes composed of type I and type II receptor subunits having serine / threonine kinase domains. After ligand binding, the type II receptor phosphorylates and activates the type I receptor, initiating a Smad-dependent signaling cascade that induces or represses transcriptional activity.
[0003] TGF-β (TGF-β1, TGF-β2, and TGF-β3) mediates Smad2 / 3 signaling through the binding and activation of high-affinity receptors TGFβRII and TGFβRIIB on the cell surface. TGF-β plays an essential role in regulating a wide range of biological activities, including immune function, cell proliferation and differentiation, fibrosis, epithelial-mesenchymal transition, hematopoiesis, myogenesis, and bone remodeling. Elevated TGF-β levels and consequently increased Smad2 / 3 signaling have been linked to the pathogenesis and progression of many disease conditions, including cancer, fibrosis, anemia, bone metastases, osteopenia, pain, muscle loss, insulin resistance, chronic kidney disease, liver disease, and cardiovascular disease.
[0004] Additionally, as a subset of the TGF-β superfamily, activin and related proteins (including activin A, activin B, activin AB, GDF-8, and GDF-11) also mediate Smad2 / 3 signaling through the binding and activation of their high-affinity receptors ActRIIA and ActRIIB on the cell surface. Activin and related proteins regulate a wide range of biological activities, including immune function, cell differentiation, myogenesis, fibrosis, bone remodeling, hematopoiesis, and reproductive physiological functions. The secreted glycoprotein, follistatin (FST), binds to activin and activin-related ligands, negatively regulating their signaling activity. Overexpression of activin and related ligands, as well as increased Smad2 / 3 signaling, has been linked to the pathogenesis and progression of many distressing conditions, such as cancer, fibrosis, anemia, bone metastases, bone fragility, fractures (factures), muscle wasting disorders, cachexia, pulmonary hypertension, pain, insulin resistance, chronic kidney disease, liver disease, myocardial infarction, and heart failure.
[0005] The TGF-β / activin-Smad2 / 3 signaling pathway plays a central role in the pathogenesis and progression of fibrosis. The key mechanism underlying the pathogenesis and progression of fibrosis is increased TGF-β / activin-Smad2 / 3 signaling, which leads to fibroblast proliferation and activation and consequently to the overexpression of extracellular matrix components in diseased tissue, such as COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, and COL6A3. Evidence indicates that both TGF-β and activin are upregulated during fibrosis. When elevated, either TGF-β or activin can trigger fibroblast activation, leading to fibrosis. Since both TGF-β and activin are elevated, it is important to inhibit not only TGF-β but also activin to more effectively attenuate fibrosis.
[0006] The TGF-β / activin-Smad2 / 3 signaling pathway also plays a crucial role in cancer pathogenesis and progression, partly due to its significant impact on tumor immune surveillance. TGF-β and activin are highly overexpressed in various cancers. Overproduction of TGF-β and activin in the tumor microenvironment results in activation of Smad2 / 3 signaling in regulatory T cells (Tregs), as well as their proliferation and activation. Increased Treg activity then leads to inhibition of CD8+ cytotoxic T cells, thereby reducing their ability to detect and eliminate cancer cells. Currently, numerous clinical trials in immuno-oncology focus on TGF-β inhibitors and T cell checkpoint inhibitors (e.g., anti-PD1 antibodies and anti-CTLA4 antibodies). However, it is important to note that both TGF-β and activin are highly overexpressed in various cancers, and elevated activin or activin-related ligands, like elevated TGF-β, can also suppress cancer immune surveillance through Treg activation. Therefore, parallel inhibition of elevated TGF-β and elevated activin more effectively attenuates Tregs, thereby more effectively restoring immune surveillance in cancer. Thus, multispecific polypeptide antagonists that have the ability to neutralize not only elevated TGF-β (i.e., TGF-β1, TGF-β2, and TGF-β3) but also elevated activin (i.e., activin A, activin B, and activin AB) in cancer may result in superior efficacy and better response rates for cancer treatment, including combination therapy with immune checkpoint inhibitors. [Overview of the project]
[0007] Disclosure of the invention In one embodiment, the present invention provides a novel polypeptide-based multispecific antagonist molecule specifically designed to simultaneously neutralize activin signaling and TGF-β signaling in a potent manner. In various embodiments, the multispecific antagonist molecule is designed as depicted in Figures 1–4.
[0008] In various embodiments, the polyspecific antagonist is a polyspecific polypeptide molecule comprising a first antigen-binding molecule ("activin-binding polypeptide") that specifically binds to an activin ligand or activin-related ligand and a second antigen-binding molecule ("TGF-β-binding polypeptide") that specifically binds to a TGF-β ligand. In various embodiments, the “activin-binding polypeptide” is selected from any polypeptide having the ability to bind to activin (i.e., activin A, activin B, or activin AB) and / or activin-related ligands (i.e., GDF8 or GDF11), including but not limited to anti-activin antibodies (including anti-activin A antibodies and anti-activin B antibodies), fragments of anti-activin antibodies, the extracellular domain (ECD) of wild-type activin 2A receptor (ActRIIA) or activin 2B receptor (ActRIIB), modified ActRIIA and ActRIIB extracellular domains, wild-type and modified native activin-binding proteins, such as follistatin, follistatin-like proteins and propeptides, and phage display-derived polypeptides that target activin or activin-related ligands, and the “TGF-β-binding polypeptide” is selected from any polypeptide having the ability to bind to activin (i.e., activin A, activin B, or activin AB) and / or activin-related ligands (i.e., GDF8 or GDF11), including anti-TGF-β antibodies, fragments of anti-TGF-β antibodies, and wild-type TGF-β The selection is made from the group consisting of type 2 receptor (including TGFβRIIA and TGFβRIIB) extracellular domains (ECDs), modified TGFβRIIA and TGFβRIIB extracellular domains, and phage display-derived antagonist polypeptides that target TGF-β ligands.
[0009] In various embodiments, the polyspecific antagonist molecule comprises an isolated antibody or its antigen-binding fragment that specifically binds to activin or an activin-related ligand, and an isolated antibody or its antigen-binding fragment that specifically binds to a TGF-β ligand. In various embodiments, the isolated antibody or its antigen-binding fragment is selected from the group consisting of monoclonal Ab (mAb), polyclonal Ab, Ab fragment (e.g., Fab, Fab', F(ab')2, Fv, Fc, etc.), chimeric Ab, mini-Ab or domain Ab (dAb), bispecific Ab, bispecific Ab, heteroconjugate Ab, single-chain Ab (SCA), single-chain variable region fragment (ScFv), humanized Ab, fully human Ab, and any other modified configuration of an immunoglobulin (Ig) molecule containing an antigen recognition site of the required specificity. In various embodiments, the polyspecific molecule comprises an isolated antibody or its antigen-binding fragment selected from the group consisting of fully human, humanized, and chimeric antibodies.
[0010] In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 1. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 2. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 3. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 4. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 5. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 6. In various embodiments, the first antigen-binding molecule specifically binds to activin or an activin-related ligand containing the amino acid sequence described in SEQ ID NO: 7. In various embodiments, the first antigen-binding molecule specifically binds to an activin or activin-related ligand containing the amino acid sequence described in SEQ ID NO: 8. In various embodiments, the first antigen-binding molecule specifically binds to an activin or activin-related ligand containing the amino acid sequence described in SEQ ID NO: 9.
[0011] In various embodiments, the first antigen-binding molecule that specifically binds to activin or an activin-related ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 10; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 11; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 10 and the light chain amino acid sequence described in SEQ ID NO: 11; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 12; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 13; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 12 and the light chain variable region amino acid sequence described in SEQ ID NO: 13.
[0012] In various embodiments, the first antigen-binding molecule that specifically binds to activin or an activin-related ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 14; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 15; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 14 and the light chain amino acid sequence described in SEQ ID NO: 15; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 16; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 17; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 16 and the light chain variable region amino acid sequence described in SEQ ID NO: 17.
[0013] In various embodiments, the second antigen-binding molecule specifically binds to a TGF-β ligand containing the amino acid sequence described in SEQ ID NO: 18. In various embodiments, the second antigen-binding molecule specifically binds to a TGF-β ligand containing the amino acid sequence described in SEQ ID NO: 19. In various embodiments, the second antigen-binding molecule specifically binds to a TGF-β ligand containing the amino acid sequence described in SEQ ID NO: 20. In various embodiments, the second antigen-binding molecule specifically binds to a TGF-β ligand containing the amino acid sequence described in SEQ ID NO: 21.
[0014] In various embodiments, the second antigen-binding molecule that specifically binds to the TGF-β ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 22; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 23; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 22 and the light chain amino acid sequence described in SEQ ID NO: 23; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 24; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 25; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 24 and the light chain variable region amino acid sequence described in SEQ ID NO: 25.
[0015] In various embodiments, the polyspecific antagonist is a polypeptide molecule comprising a first antigen-binding molecule that specifically binds to an activin ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand, wherein the activin ligand-binding molecule is selected from the group of polypeptides comprising the amino acid sequences described in SEQ ID NOs: 1 to 17, and the TGF-β ligand-binding molecule is selected from the group of polypeptides comprising the amino acid sequences described in SEQ ID NOs: 18 to 25.
[0016] In various embodiments, the polyspecific antagonist is a polypeptide molecule comprising a first antigen-binding molecule that specifically binds to an activin ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand, wherein the polyspecific molecule is selected from the group comprising a heavy chain selected from heavy chains containing amino acid sequences described in SEQ ID NOs. 72-84 and a light chain selected from light chains containing amino acid sequences described in SEQ ID NOs. 11, 13, 15, 17, 19, 21, 23, and 25.
[0017] In various embodiments, the polyspecific antagonist is a polyspecific polypeptide molecule comprising a first antigen-binding molecule that specifically binds to an activin ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand, and the polyspecific molecule is selected from the group consisting of polyspecific polypeptide molecules comprising the amino acid sequences described in SEQ ID NOs. 54 to 71.
[0018] In another aspect, the present invention provides a novel polypeptide-based bifunctional multispecific antagonist molecule specifically designed to simultaneously inhibit TGF-β, activin, and T cell immune checkpoints (including PD1, PDL1 or CTLA4). In various embodiments, the bifunctional multispecific antagonist is a bifunctional multispecific molecule comprising a first antigen-binding molecule (an "activin-binding polypeptide") that specifically binds to an activin ligand or an activin-related ligand, a second antigen-binding molecule (a "TGF-β-binding polypeptide") that specifically binds to a TGF-β ligand, and a third antigen-binding molecule (a "PD-1 / PD-L1 / CTLA-4-binding polypeptide") that specifically binds to any one of a PD-1 ligand, a PD-L1 ligand or a CTLA-4 ligand. In various embodiments, the bifunctional multispecific antagonist molecule is designed as depicted in FIGS. 5-6.
[0019] In various embodiments, the third antigen-binding molecule that specifically binds to a PD-1 ligand is an isolated antibody selected from the group consisting of an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 26; an antibody comprising the light chain amino acid sequence set forth in SEQ ID NO: 27; an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 26 and the light chain amino acid sequence set forth in SEQ ID NO: 27; an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 28; an antibody comprising the light chain variable region amino acid sequence set forth in SEQ ID NO: 29; and an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 28 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 29.
[0020] In various embodiments, the third antigen-binding molecule that specifically binds to a PD-1 ligand is an isolated antibody selected from the group consisting of an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 30; an antibody comprising the light chain amino acid sequence set forth in SEQ ID NO: 31; an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 30 and the light chain amino acid sequence set forth in SEQ ID NO: 31; an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 32; an antibody comprising the light chain variable region amino acid sequence set forth in SEQ ID NO: 33; and an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 32 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 33.
[0021] In various embodiments, the third antigen-binding molecule that specifically binds to a PD-1 ligand is an isolated antibody selected from the group consisting of an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 38; an antibody comprising the light chain amino acid sequence set forth in SEQ ID NO: 39; an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 38 and the light chain amino acid sequence set forth in SEQ ID NO: 39; an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 40; an antibody comprising the light chain variable region amino acid sequence set forth in SEQ ID NO: 41; and an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 40 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 41.
[0022] In various embodiments, the third antigen-binding molecule that specifically binds to a PD-1 ligand is an isolated antibody selected from the group consisting of an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 42; an antibody comprising the light chain amino acid sequence set forth in SEQ ID NO: 43; an antibody comprising the heavy chain amino acid sequence set forth in SEQ ID NO: 42 and the light chain amino acid sequence set forth in SEQ ID NO: 43; an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 44; an antibody comprising the light chain variable region amino acid sequence set forth in SEQ ID NO: 45; and an antibody comprising the heavy chain variable region amino acid sequence set forth in SEQ ID NO: 44 and the light chain variable region amino acid sequence set forth in SEQ ID NO: 45.
[0023] In various embodiments, the third antigen-binding molecule that specifically binds to the CTLA-4 ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 34; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 35; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 34 and the light chain amino acid sequence described in SEQ ID NO: 35; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 36; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 37; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 36 and the light chain variable region amino acid sequence described in SEQ ID NO: 37.
[0024] In various embodiments, the third antigen-binding molecule that specifically binds to the PD-L1 ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 46; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 47; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 46 and the light chain amino acid sequence described in SEQ ID NO: 47; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 48; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 49; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 48 and the light chain variable region amino acid sequence described in SEQ ID NO: 49.
[0025] In various embodiments, the third antigen-binding molecule that specifically binds to the PD-L1 ligand is an isolated antibody selected from the group consisting of: an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 50; an antibody containing the light chain amino acid sequence described in SEQ ID NO: 51; an antibody containing the heavy chain amino acid sequence described in SEQ ID NO: 50 and the light chain amino acid sequence described in SEQ ID NO: 51; an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 52; an antibody containing the light chain variable region amino acid sequence described in SEQ ID NO: 53; and an antibody containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 52 and the light chain variable region amino acid sequence described in SEQ ID NO: 53.
[0026] In various embodiments, a bifunctional, multispecific antagonist is a bifunctional, multispecific molecule comprising a first antigen-binding polypeptide that specifically binds to an activin ligand, a second antigen-binding polypeptide that specifically binds to a TGF-β ligand, and a third antigen-binding polypeptide that specifically binds to any of PD-1 ligand, PD-L1 ligand, or CTLA-4 ligand. The bifunctional, multispecific molecule is selected from the group comprising a heavy chain selected from heavy chains containing amino acid sequences described in SEQ ID NOs. 85-120 and a light chain selected from light chains containing amino acid sequences described in SEQ ID NOs. 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, and 53. In various embodiments, a bifunctional, multispecific antagonist molecule is a bifunctional, multispecific antagonist molecule comprising a heavy chain selected from heavy chains containing amino acid sequences described in SEQ ID NOs. 85-102 and a light chain containing an amino acid sequence described in SEQ ID NO. 27. In various embodiments, the bifunctional, multispecific antagonist molecule is a bifunctional, multispecific antagonist molecule comprising a heavy chain selected from the heavy chains containing the amino acid sequences described in SEQ ID NOs. 103-120 and a light chain containing the amino acid sequence described in SEQ ID NOs. 35.
[0027] In another embodiment, the disclosure provides a pharmaceutical composition comprising an isolated polyspecific or bifunctional polyspecific antagonist molecule mixed with a pharmaceutically acceptable carrier.
[0028] In another embodiment, the present disclosure provides methods for treating or preventing various complex disease conditions whose pathogenesis involves the parallel activation of activin signaling and TGF-β signaling.
[0029] In various embodiments, the novel polyspecific or bifunctional polyspecific antagonist molecules of the present invention are used to treat the following conditions: Hematological disorders: ineffective erythropoiesis, anemia, pancytopenia, myelodysplastic syndrome; Fibrotic diseases: non-alcoholic steatohepatitis / NASH, hepatic fibrosis, pulmonary fibrosis, renal fibrosis, polycystic kidney disease, cardiac fibrosis, muscular fibrosis, myelofibrosis, cutaneous fibrosis, and ocular fibrosis; Hematological malignancies: multiple myeloma, leukemia, and lymphoma; Solid cancers: melanoma, multiple myeloma, lung cancer, pancreatic cancer, colorectal cancer, liver cancer, stomach cancer, kidney cancer, bladder cancer, head and neck cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, testicular cancer, prostate cancer, brain cancer, and sarcoma; Metastases: bone metastases, lung metastases, liver metastases, brain metastases; Checkpoint inhibitors, For example, cancer treatment in combination with anti-PD1, anti-PDL1, and anti-CTL4 antibodies; neuromuscular diseases: muscular dystrophy, spinal muscular atrophy, spinal cord injury, stroke; pain: nociceptive pain, neuropathic pain; wasting disorders: sarcopenia, cancer cachexia, cardiac cachexia, renal cachexia, rheumatic cachexia, and anorexia nervosa; bone disorders: bone metastases, skeletal events in cancer, bone fragility, fractures, osteopenia, and osteoporosis; cardiovascular diseases: pulmonary hypertension, myocardial infarction, heart failure; metabolic disorders: insulin resistance, diabetic nephropathy, chronic kidney disease; inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease; infections: SARS-CoV, cytokine storm syndrome, sepsis; and trauma: including, but not limited to, burns, it may have broad applications for the treatment of various disorders.
[0030] In another embodiment, the present disclosure provides the use of a bifunctional or bifunctional multispecific antagonist molecule for manufacturing a pharmacopoeia for the treatment of any disorder or condition described herein.
[0031] In another embodiment, the Disclosure provides isolated nucleic acid molecules comprising polynucleotides encoding polyspecific or bifunctional polyspecific antagonist molecules of the Disclosure. In various embodiments, the isolated nucleic acid molecule comprises polynucleotides described herein and further comprises polynucleotides encoding at least one heterologous protein described herein. In various embodiments, the nucleic acid molecule further comprises polynucleotides encoding linkers or hinge linkers described herein.
[0032] In another embodiment, the Disclosure provides a vector comprising the nucleic acid described herein. In various embodiments, the vector is an expression vector. In another embodiment, the Disclosure provides isolated cells comprising the nucleic acid of the Disclosure. In various embodiments, the cells are host cells comprising the expression vector of the Disclosure. In another embodiment, a method is provided for producing a polyspecific or bifunctional polyspecific antagonist molecule, comprising culturing a host cell under conditions that promote the expression of the protein or polypeptide.
[0033] In another embodiment, the present invention provides a method for producing a multispecific antagonist molecule or a bifunctional multispecific antagonist molecule comprising an activin or activin-related ligand described herein, such as a first antigen-binding molecule that specifically binds to GDF8 or GDF11, and a second antigen-binding molecule that specifically binds to TGF-β, the method comprising: a) transforming host cells with a vector comprising a polynucleotide encoding the multispecific or bifunctional multispecific antagonist molecule; b) culturing the host cells under conditions suitable for the expression of the multispecific or bifunctional multispecific antagonist molecule; and c) recovering the bifunctional antagonist molecule from the culture. The present invention also encompasses multispecific or bifunctional multispecific antagonist molecules produced by the method of the present invention. [Brief explanation of the drawing]
[0034] [Figure 1] Figure 1 illustrates a representative mulrispecific antagonist molecule of the present invention. The “activin-binding polypeptide” shown in this diagram refers to any polypeptide having the ability to bind to activin (i.e., activin A, activin B, or activin AB) and / or activin-related ligands (i.e., GDF8 or GDF11), including, but not limited to, 1) anti-activin antibodies (including anti-activin A antibodies and anti-activin B antibodies), fragments of anti-activin antibodies, wild-type activin 2A receptor (ActRIIA) or activin 2B receptor (ActRIIB) extracellular domains (ECD), modified ActRIIA and ActRIIB extracellular domains, wild-type and modified native activin-binding proteins, such as follistatin, follistatin-like proteins and propeptides, and phage display-derived polypeptides having the ability to bind to and sequester activin and / or activin-related ligands. The “TGF-β-binding polypeptide” shown in this diagram refers to any polypeptide capable of binding to TGF-β (i.e., TGF-β1, TGF-β2, or TGF-β3), including, but not limited to, anti-TGF-β antibodies, fragments of anti-TGF-β antibodies, the extracellular domain (ECD) of wild-type TGF-β type 2 receptors (including TGFβRIIA and TGFβRIIB), modified TGFβRIIA and TGFβRIIB extracellular domains, and phage display-derived antagonist polypeptides capable of binding to and neutralizing TGF-β. The “linker” shown in this diagram refers to various methods of fusing different polypeptide fusion partners to produce bispecific and polyspecific molecules, including, but not limited to, the use of any peptide linker or chemical linker. [Figure 2] Figure 2 depicts the two bifunctional antagonist molecules of the present invention in different configurations (Figure 2A and Figure 2B), where the activin-binding polypeptide is an activin receptor ECD and the TGF-β-binding polypeptide is a TGF-β receptor ECD attached via an Fc domain. [Figure 3] Figures 3A and 3B depict two representative bifunctional antagonist molecules of the present invention, wherein (A) the activin-binding polypeptide is an anti-activin antibody and the TGF-β-binding polypeptide is attached to the heavy chain CH3 of the anti-activin antibody via a linker to a TGF-β receptor ECD; or (B) the TGF-β-binding polypeptide is an anti-TGF-β antibody and the activin-binding polypeptide is attached to the heavy chain CH3 of the anti-TGF-β antibody via a linker to an activin receptor ECD. In alternative embodiments, the TGF-β receptor ECD (or TNF receptor ECD) is attached to the anti-activin antibody (or anti-TGF-β antibody) via a linker in the heavy chain variable region (VH) of the antibody. In alternative embodiments, the TGF-β receptor ECD (or activin receptor ECD) is attached to the anti-activin antibody (or anti-TGF-β antibody) via a linker in the light chain variable region (VL) of the antibody. In an alternative embodiment, the TGF-β receptor ECD (or TNF receptor ECD) is attached to the anti-activin antibody (or anti-TGF-β antibody) via a linker at an internal site rather than at the heavy chain CH3, VL, or VH site of the antibody. [Figure 4] Figure 4 illustrates the bifunctional antagonist molecule of the present invention in the form of a bispecific antibody, in which the activin-binding polypeptide is represented by the variable regions (VL and VH) of an anti-activin A antibody, and the TGF-β-binding polypeptide is represented by the variable regions (VL and VH) of an anti-TGF-β antibody. The bispecific antibody depicted in Figure 4 is merely an example, and bispecific antibodies containing variable regions from anti-TGF-β antibodies and anti-activin antibodies can be constructed in a variety of configurations different from the example depicted in Figure 4. [Figure 5]Figure 5 depicts a representative novel bifunctional, multispecific antagonist molecule of the present invention that has the ability to inhibit T cell immune checkpoints, activin, and TGF-β through fusion between an immune checkpoint inhibitor polypeptide (e.g., an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody heavy chain) (fusion partner A), an activin-binding polypeptide (fusion partner B), and a TGFβ-binding polypeptide (fusion partner C). The “immune checkpoint inhibitor polypeptide” shown in this diagram refers to any antagonist polypeptide that has the ability to bind to and inhibit PD-1, PD-L1, or CTLA-4, including but not limited to anti-PD1, anti-PD-L1, and anti-CTLA-4 antibodies or antibody fragments, as well as PD-1 decoy receptor polypeptides. The “activin-binding polypeptide” shown in this diagram refers to any polypeptide capable of binding to activin (i.e., activin A, activin B, or activin AB) and / or activin-related ligands (i.e., GDF8 or GDF11), including, but not limited to, 1) anti-activin antibodies (including anti-activin A antibodies and anti-activin B antibodies), fragments of anti-activin antibodies, the extracellular domain (ECD) of wild-type activin 2A receptor (ActRIIA) or activin 2B receptor (ActRIIB), modified ActRIIA and ActRIIB extracellular domains, wild-type and modified native activin-binding proteins, such as follistatin, follistatin-like proteins and propeptides, and phage display-derived polypeptides capable of binding to and sequestering activin and / or activin-related ligands.The “TGFβ-binding polypeptides” shown in this diagram refer to any polypeptide capable of binding to TGFβ (i.e., TGFβ1, TGFβ2, or TGFβ3), including, but not limited to, anti-activin antibodies, fragments of anti-TGFβ antibodies, extracellular domains (ECDs) of wild-type TGFβ type 2 receptors (including TGFβRIIA and TGFβRIIB), modified TGFβRIIA and TGFβRIIB extracellular domains, and phage display-derived antagonist polypeptides capable of binding to and neutralizing TGFβ. The “linkers” shown in this diagram refer to various methods of fusing different polypeptide fusion partners to produce bispecific and polyspecific molecules, including, but not limited to, the use of any peptide linker or chemical linker. [Figure 6] Figures 6A and 6B depict two representative bifunctional antagonist molecules of the present invention, wherein (A) the immune checkpoint inhibitor polypeptide is an anti-PD-1 antibody, the activin-binding polypeptide is an activin receptor ECD attached to the heavy chain CH3 of the anti-PD-1 antibody via a linker, and the TGF-β-binding polypeptide is a TGF-β receptor ECD attached to the activin receptor ECD via a linker; or (B) the immune checkpoint inhibitor polypeptide is an anti-CTLA-4 antibody, the activin-binding polypeptide is an activin receptor ECD attached to the heavy chain CH3 of the anti-CTLA-4 antibody via a linker, and the TGF-β-binding polypeptide is a TGF-β receptor ECD attached to the activin receptor ECD via a linker. [Figure 7] Figure 7 depicts line graphs showing that the multispecific antagonist molecules A115, A116, A117, and A118 potently neutralize activin A and activin B in cell-based assays. IC50 values were calculated and plotted using Prism software (GraphPad Software). [Figure 8]Figure 8 depicts line graphs showing that the multispecific antagonist molecules A115, A116, A117, and A118 potently neutralize TGF-β1 and TGF-β3 in cell-based assays. IC50 values were calculated and plotted using Prism software (GraphPad Software). [Figure 9] Figure 9 depicts line graphs showing that the multispecific antagonist molecules A115, A116, A117, and A118 potently neutralize GDF-8 and GDF-11 in cell-based assays. IC50 values were calculated and plotted using Prism software (GraphPad Software). [Figure 10] Figures 10A to 10E illustrate the inhibitory effects of the multispecific antagonist A116 on cell migration and colony formation in A549 human non-small cell lung cancer cell cultures. [Figure 11] Figures 11A to 11G illustrate the inhibitory effects of the multispecific antagonist A116 on cell migration and colony formation in A549 human non-small cell lung cancer cell cultures. [Figure 12] Figure 12 illustrates the inhibitory effect of the multispecific antagonist A116 on cell migration and colony formation in A549 human non-small cell lung cancer cell cultures. [Figure 13] Figures 13A–13F show histological images of H&E-stained lung sections and Ashcraft scores of lung sections in a mouse model of bleomycin-induced pulmonary fibrosis. Data indicate that dual inhibition of TGF-β and activin with A116 significantly reduced bleomycin-induced pulmonary fibrosis, while the activin inhibitor ActRIIA-Fc or the TGF-β blocker TGFRII-Fc moderately inhibited bleomycin-induced pulmonary fibrosis. Analysis of Ashcraft scores revealed that A116 treatment resulted in a greater reduction of pulmonary fibrosis compared to ActRIIA-Fc or TGFRII-Fc treatment. [Figure 14]Figures 14A–14F depict histological images of Masson trichrome-stained lung sections from mice with bleomycin-induced pulmonary fibrosis and bar graphs illustrating the quantitative analysis of collagen deposition area in the lung sections. The data demonstrate that A116 was more effective in attenuating collagen deposition than ActRIIA-Fc or TGFRII-Fc in the bleomycin-induced pulmonary fibrosis model. [Figure 15] Figures 15A–15E show histological images of immunochemical staining for α-SMA, a marker of fibrosis, in lung sections from control and bleomycin-treated mice. Lung sections were immunostained with a primary anti-α-SMA antibody in combination with an HRP-labeled secondary antibody. The results indicate that A116 was more effective than ActRIIA-Fc or TGFRII-Fc in preventing the induction of α-SMA in the lungs of bleomycin-treated mice. [Modes for carrying out the invention]
[0035] Forms for implementing this disclosure definition The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acid residues. In various embodiments, “peptide,” “polypeptide,” and “protein” are chains of amino acids whose alpha carbons are linked through peptide bonds. The terminal amino acid at one end of the chain (amino-terminus) therefore has a free amino group, and the terminal amino acid at the other end of the chain (carboxy-terminus) has a free carboxyl group. Where used herein, the term “amino-terminus” (abbreviated as N-terminus) refers to the free α-amino group on the amino acid at the amino-terminus of a peptide or the α-amino group (imino group if participating in a peptide bond) of an amino acid at any other position within the peptide. Similarly, the term “carboxy-terminus” refers to the free carboxyl group at the carboxy-terminus of a peptide or the carboxyl group of an amino acid at any other position within the peptide. Peptides also include, but are not limited to, peptide mimes, such as amino acids linked by ethers as opposed to amide bonds, essentially any polyamino acid.
[0036] The polypeptides of this disclosure include polypeptides that have been modified in any way and for any reason to (1) reduce susceptibility to protein hydrolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity, and (5) confer or alter other physicochemical or functional properties.
[0037] When used herein, amino acid "substitution" refers to the substitution of one amino acid at a specific position in the parent polypeptide sequence with a different amino acid within the polypeptide. Amino acid substitutions can be produced using genetic or chemical methods well known in the art. For example, one or more amino acid substitutions (e.g., conserved amino acid substitutions) may occur in naturally occurring sequences (e.g., in portions of the polypeptide outside domains that form intermolecular contacts). A "conserved amino acid substitution" refers to the substitution of an amino acid in a polypeptide with a functionally similar amino acid. Each of the following six groups contains amino acids that are conserved substitutions with respect to each other: 1) Alanine (A), serine (S), and threonine (T) 2) Aspartic acid (D) and glutamic acid (E) 3) Asparagine (N) and glutamine (Q) 4) Arginine(R) and Lysine(K) 5) Isoleucine (I), leucine (L), methionine (M), and valine (V) 6) Phenylalanine (F), tyrosine (Y), and tryptophan (W)
[0038] A "non-conservative amino acid substitution" refers to the substitution of a member of one of these classes with a member from another class. In making such a change, the hydroxyl index of the amino acids may be considered according to various embodiments. Each amino acid is assigned a hydroxyl index based on its hydrophobic and electrostatic characteristics. These are isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
[0039] The importance of hydroxyl amino acid indices in conferring interactive biological functions to proteins is well understood in the art (see, for example, Kyte et al., 1982, J. Mol. Biol. 157:105-131). It is known that certain amino acids can be substituted with other amino acids having similar hydroxyl indices or scores, while still retaining similar biological activity. When making changes based on hydroxyl indices, various embodiments include substitutions of amino acids whose hydroxyl indices are within ±2; various embodiments include substitutions within ±1; and various embodiments include substitutions within ±0.5.
[0040] Substitutions of similar amino acids can be effectively carried out based on hydrophilicity, and this is also understood in the Art, particularly when the resulting biologically functional protein or peptide is intended for use in immunological embodiments, as disclosed herein. In various embodiments, the maximum local mean hydrophilicity of a protein, such that it is governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., the biological properties of the protein.
[0041] The following hydrophilic values are assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0 ± 1); glutamic acid (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 ± 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). When making changes based on similar hydrophilicity values, various embodiments include substitutions of amino acids whose hydrophilicity value is within ±2, within ±1, and within ±0.5.
[0042] Examples of amino acid substitutions are listed in Table 1. TIFF2023548399000002.tif200170
[0043] Those skilled in the art can determine preferred variants of the polypeptides described herein using well-known techniques. In various embodiments, those skilled in the art may identify preferred segments of the molecule that can be altered without disrupting activity by targeting regions considered insignificant for activity. In other embodiments, those skilled in the art can identify conserved molecular residues and segments among similar polypeptides. In further embodiments, segments that may be important for biological activity or structure may be subjected to conserved amino acid substitution without disrupting biological activity or adversely affecting the polypeptide structure.
[0044] Additionally, those skilled in the art may consider structure-function studies to identify residues in similar polypeptides that are important for activity or structure. Taking such comparisons into account, those skilled in the art can predict the importance of amino acid residues in a polypeptide corresponding to amino acid residues that are important for activity or structure in similar polypeptides. Those skilled in the art may select chemically similar amino acid substitutions for such predicted important amino acid residues.
[0045] Those skilled in the art can also analyze the three-dimensional structure of similar polypeptides and the amino acid sequences associated with that structure. Considering such information, those skilled in the art may predict the alignment of amino acid residues of the polypeptide with respect to its three-dimensional structure. In various embodiments, those skilled in the art may choose not to make radical changes to amino acid residues that are expected to be on the surface of the polypeptide, because such residues may be involved in important interactions with other molecules. Furthermore, those skilled in the art may generate test variants containing a single amino acid substitution at each desired amino acid residue. These variants can then be screened using activity assays known to those skilled in the art. Such variants can be used to gather information about preferred variants. For example, if a change to a particular amino acid residue is found to result in disruption, undesirable reduction, or unsuitable activity, variants with such changes can be avoided. In other words, based on the information gathered from such routine experiments, those skilled in the art can easily determine which amino acids should be avoided, either alone or in combination with other mutations.
[0046] The terms “polypeptide fragment” and “cleaved polypeptide,” as used herein, refer to polypeptides having amino-terminal and / or carboxy-terminal deletions compared to the corresponding full-length protein. In various embodiments, the fragments may be, for example, at least 5, at least 10, at least 25, at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 600, at least 700, at least 800, at least 900, or at least 1000 amino acids in length. In various embodiments, the fragment can also be, for example, up to 1000, up to 900, up to 800, up to 700, up to 600, up to 500, up to 450, up to 400, up to 350, up to 300, up to 250, up to 200, up to 150, up to 100, up to 50, up to 25, up to 10, or up to 5 amino acids in length. The fragment may further include one or more additional amino acids at either or both of its ends, for example, a sequence of amino acids from different naturally occurring proteins (e.g., Fc or leucine zipper domain) or an artificial amino acid sequence (e.g., an artificial linker sequence).
[0047] The terms “polypeptide variant,” “hybrid polypeptide,” and “polypeptide mutant,” as used herein, refer to a polypeptide comprising an amino acid sequence in which one or more amino acid residues are inserted, deleted, and / or substituted compared to another polypeptide sequence. In various embodiments, the number of amino acid residues inserted, deleted, or substituted can be, for example, at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 225, at least 250, at least 275, at least 300, at least 350, at least 400, at least 450, or at least 500 amino acid lengths. The hybrids of this disclosure include fusion proteins.
[0048] A polypeptide "derivative" is a polypeptide that has been chemically modified, for example, by conjugation to another chemical moiety, such as polyethylene glycol, albumin (e.g., human serum albumin), phosphorylation, and glycosylation.
[0049] The term “% sequence identity” (sequence identity %) is used herein interchangeably with the term “% identity” (identity %) and refers to the level of amino acid sequence identity between two or more peptide sequences or the level of nucleotide sequence identity between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% identity means the same as 80% sequence identity determined by a defined algorithm, meaning that a given sequence is at least 80% identical to another sequence. In various embodiments, identity % is selected from, for example, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or higher sequence identity to a given sequence. In various embodiments, the identity percentage is, for example, within the range of about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0050] The term “% sequence homology” (sequence homology%) is used herein interchangeably with the term “% homology” (homology%) and refers to the level of amino acid sequence homology between two or more peptide sequences or the level of nucleotide sequence homology between two or more nucleotide sequences when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same as 80% sequence homology determined by a defined algorithm, so that homologs of a given sequence have a sequence homology higher than 80% over the length of a given sequence. In various embodiments, homology% is selected from, for example, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% or higher sequence homology to a given sequence. In various embodiments, the homology percentage is, for example, in the range of about 60% to about 70%, about 70% to about 80%, about 80% to about 85%, about 85% to about 90%, about 90% to about 95%, or about 95% to about 99%.
[0051] Exemplary computer programs that can be used to determine identity between two sequences include, but are not limited to, a set of BLAST programs publicly available on the NCBI website, such as BLASTN, BLASTX, and TBLASTX, BLASTP, and TBLASTN. See also Altschul et al., J.Mol.Biol.215:403-10, 1990 (the published default settings, i.e., parameters w=4, t=17, are particularly referenced) and Altschul et al., Nucleic Acids Res., 25:3389-3402, 1997. Sequence searches are typically performed using the BLASTP program when evaluating a given amino acid sequence against amino acid sequences in GenBank Protein Sequences and other public databases. The BLASTX program is preferred for searching for nucleic acid sequences translated in all reading frames against amino acid sequences in GenBank Protein Sequences and other public databases. Both BLASTP and BLASTX are run using the default parameters of an open gap penalty of 11.0 and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix.
[0052] In addition to calculating the sequence identity percentage, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA, 90:5873-5787, 1993). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indicator of the probability that a match between two nucleotide or amino acid sequences will occur by chance. For example, if the minimum sum probability in the comparison of the test nucleic acid with the reference nucleic acid is, for example, less than approximately 0.1, less than approximately 0.01, or less than approximately 0.001, the nucleic acid is considered similar to the reference sequence.
[0053] The terms “modification” or “alteration,” as used herein, refer to any manipulation of the peptide backbone (e.g., amino acid sequence) or post-translational modifications (e.g., glycosylation) of a polypeptide.
[0054] The term "antigen-binding molecule," as used herein, refers in its broadest sense to a molecule that specifically binds to an antigen-determining factor. Examples of antigen-binding molecules are antibodies, antibody fragments, and scaffold antigen-binding proteins. An "antigen-binding molecule that binds to the same epitope as a reference molecule" refers to an antigen-binding molecule that blocks the binding of the reference molecule to its antigen by 50% or more in a competitive assay, and conversely, a reference molecule that blocks the binding of the antigen-binding molecule to its antigen by 50% or more in a competitive assay.
[0055] As used herein, the term “antigen-binding site” refers to a portion of an antigen-binding molecule that specifically binds to an antigen-determining factor. More specifically, the term “antigen-binding site” refers to a portion of an antibody that specifically binds to a portion or all of an antigen and includes a compartment complementary to that portion or all of the antigen. If the antigen is large, the antigen-binding molecule may bind to only a specific portion of the antigen, which is referred to as an epitope. The antigen-binding site may be provided, for example, by one or more variable domains (also called variable regions). Preferably, the antigen-binding site includes an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).
[0056] As used herein, the term “antigen-determinant” is synonymous with “antigen” and “epitope” and refers to a site on a polypeptide macromolecule (e.g., a conformational arrangement made up of a continuous stretch of amino acids or different regions of discontinuous amino acids) to which an antigen-binding moiety binds to form an antigen-binding moiety-antigen complex. Useful antigen-determinants may be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or in the extracellular matrix (ECM). Proteins useful as antigens herein, unless otherwise indicated, may be proteins in any native form from any vertebrate source, including mammals, e.g., primates (e.g., humans) and rodents (e.g., mice and rats). In various embodiments, the antigen is a human protein.
[0057] In this specification, the term "antibody" is used in its broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, monospecific and polyspecific antibodies (e.g., bispecific antibodies), and antibody fragments insofar as they exhibit desired antigen-binding activity.
[0058] The term "chimeric" antibody refers to an antibody in which the heavy chain and / or light chain portion originates from a specific source or species, while the rest of the heavy chain and / or light chain originates from a different source or species.
[0059] A “humanized” antibody refers to a chimeric antibody containing amino acid residues from a non-human HVR and amino acid residues from a human FR. In certain embodiments, a humanized antibody contains substantially all of at least one, and typically two, variable domains, where all or substantially all of the HVR (e.g., CDR) corresponds to that of a non-human antibody, and all or substantially all of the FR corresponds to that of a human antibody. A humanized antibody may optionally contain at least a portion of the antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. Other forms of “humanized antibodies” encompassed by the present invention are antibodies in which the constant region has been additionally modified or altered from that of the original antibody to produce the properties according to the present invention, particularly with respect to C1q binding and / or Fc receptor (FcR) binding.
[0060] A "human" antibody is an antibody that is produced by a human or human cell, or has an amino acid sequence that corresponds to the amino acid sequence of an antibody derived from a non-human source that utilizes the human antibody repertoire or other human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies that contain non-human antigen-binding residues.
[0061] When used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible variant antibodies, such as naturally occurring mutations or those arising during the manufacture of the monoclonal antibody preparation, and such variants are generally present in trace amounts. In contrast to polyclonal antibody preparations, which typically contain different antibodies directed to different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed to a single determinant on an antigen.
[0062] The term "monospecific" antibody, as used herein, refers to an antibody having one or more binding sites, each binding to the same epitope of the same antigen. The term "bispecific" means that an antibody can specifically bind to at least two distinct antigen-determinants, for example, each of the two binding sites being formed by a pair of antibody heavy chain variable domains (VH) and antibody light chain variable domains (VL) that bind to different antigens or different epitopes on the same antigen. Such a bispecific antibody is in a 1+1 format. Other bispecific antibody formats are a 2+1 format (containing two binding sites for a first antigen or epitope and one binding site for a second antigen or epitope) or a 2+2 format (containing two binding sites for a first antigen or epitope and two binding sites for a second antigen or epitope). Typically, a bispecific antibody contains two antigen-binding sites, each specific to a different antigen-determinant.
[0063] The term "valent," as used within this application, refers to the presence of a specified number of binding sites in an antigen-binding molecule. Therefore, the terms "bivalent," "tetravalent," and "hexavalent" refer to the presence of two, four, and six binding sites, respectively, in the antigen-binding molecule. The bispecific antibodies according to the present invention are at least "bivalent," and may be "trivalent" or "polyvalent" (e.g., "tetravalent" or "hexavalent"). In various embodiments, the antibodies of the present invention are bispecific, having two or more binding sites. That is, an antibody can be bispecific even if it has more than two binding sites (i.e., the antibody is trivalent or polyvalent). In particular, the present invention relates to a bispecific bivalent antibody having one binding site for each antigen to which it specifically binds.
[0064] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably herein to refer to antibodies having a structure substantially similar to that of a native antibody. “Native antibody” refers to naturally occurring immunoglobulin molecules with a variety of structures. For example, a native IgG class antibody is a heterotetrameric glycoprotein with approximately 150,000 daltons, composed of two disulfide-linked light chains and two heavy chains. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called a variable heavy chain domain or heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also called heavy chain constant regions. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called a variable light chain domain or light chain variable domain, followed by a light chain constant domain (CL), also called a light chain constant region. The heavy chain of an antibody can be assigned to one of five types called alpha (IgA), delta (IgD), epsilon (IgE), gamma (IgG), or mu (IgM), some of which can be further divided into subtypes, e.g., gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3), gamma 4 (IgG4), alpha 1 (IgA1), and alpha 2 (IgA2). The light chain of an antibody can be assigned to one of two types called kappa and lambda, based on the amino acid sequence of its constant domain.
[0065] An "antibody fragment" refers to a molecule other than an intact antibody that contains a portion of the intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies, triabodies, tetrabodies, cross-Fab fragments; linear antibodies; single-chain antibody molecules (e.g., scFv); and polyspecific antibodies and single-domain antibodies formed from antibody fragments, including but not limited to these. For a review of a particular antibody fragment, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of the scFv fragment, see, for example, Pluckthun, The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); and also International Publication No. 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For a discussion of the Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and having increased in vivo half-lives, see U.S. Patent No. 5,869,046. A diabody is an antibody fragment having two antigen-binding sites, which may be bivalent or bispecific; see, for example, European Patent No. 404,097; International Publication No. 1993 / 01161; Hudson et al., Nat Med 9,129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90,6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9,129-134 (2003). A single-domain antibody is an antibody fragment containing all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (see, for example, Domantis, Inc., Waltham, Mass.; U.S. Patent No. 6,248,516 B1).Additionally, the antibody fragment comprises a single-chain polypeptide having a VH domain that can be assembled with a VL domain into a functional antigen-binding molecule, or a VL domain that can be assembled with a VH domain into a functional antigen-binding molecule, thereby providing the antigen-binding properties of a full-length antibody. The antibody fragment can be produced by a variety of techniques, including but not limited to production by recombinant host cells (e.g., Escherichia coli or phages), as described herein, in addition to the proteolytic degradation of intact antibodies.
[0066] Papain digestion of an intact antibody produces two identical antigen-binding fragments, also known as “Fab” fragments, each containing heavy and light chain variable domains, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. As used herein, the term “Fab fragment” therefore refers to the light chain fragment containing the VL domain and the constant domain (CL) of the light chain, and the antibody fragment containing the VH domain and the first constant domain (CH1) of the heavy chain. The Fab' fragment is distinguished from the Fab fragment by the addition of several residues at the carboxyl terminus of the heavy chain CH1 domain, which contains one or more cysteines from the antibody hinge region. Fab'-SH is a Fab' fragment in which the cysteine residue of the constant domain has a free thiol group. Pepsin treatment yields an F(ab')2 fragment having two antigen-binding sites (two Fab fragments) and a portion of the Fc region.
[0067] A "single-chain Fab fragment" or "scFab" is a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domain and the linker have one of the following sequences in the direction from the N-terminus to the C-terminus: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL; and the linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single-chain Fab fragment is stabilized via a native disulfide bond between the CL domain and the CH1 domain. Additionally, these single-chain Fab molecules can be further stabilized by the formation of interchain disulfide bonds via the insertion of cysteine residues (e.g., at position 44 in the variable heavy chain and position 100 in the variable light chain, according to Kabat numbering).
[0068] A "single-chain variable fragment (scFv)" is a fusion protein of the variable regions of the heavy (VH) and light (VL) chains of an antibody, linked by a short linker peptide of 10 to approximately 25 amino acids. The linker is usually rich in serine or threonine for solubility, in addition to glycine for flexibility, and can connect the N-terminus of the VH to the C-terminus of the VL, or vice versa. This protein retains the specificity of the original antibody despite the removal of the constant region and the introduction of the linker. scFv antibodies are described, for example, in Houston, JS, Methods in Enzymol. 203 (1991) 46-96. Additionally, the antibody fragment contains a single-chain polypeptide that possesses the characteristics of a VH domain that can be assembled into a functional antigen-binding site together with the VL domain, or the characteristics of a VL domain that can be assembled into a functional antigen-binding site together with the VH domain, thereby providing the antigen-binding properties of a full-length antibody.
[0069] In this specification, the terms “Fc domain” or “Fc region” are used to define the C-terminal region of an antibody heavy chain that includes at least a portion of the constant region. The terms include native sequence Fc regions and variant Fc regions. In particular, the human IgG heavy chain Fc region extends from Cys226 or Pro230 of the heavy chain to the carboxyl terminus. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. The amino acid sequence of the heavy chain is always shown with the C-terminal lysine, but variants without the C-terminal lysine are included in the present invention.
[0070] The IgG Fc region contains IgG CH2 and IgG CH3 domains. The “CH2 domain” of the human IgG Fc region typically extends from approximately position 231 to approximately position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain as used herein may be a native sequence CH2 domain or a variant CH2 domain. The “CH3 domain” includes a stretch of residues at the C-terminus relative to the CH2 domain in the Fc region (i.e., from approximately position 341 to approximately position 447 of IgG). The CH3 region as used herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having an introduced “nob” on one chain and a corresponding introduced “hole” on the other chain; see U.S. Patent No. 5,821,333 expressly incorporated herein by reference). Such a variant CH3 domain may be used to facilitate heterodimerization of two non-identical antibody heavy chains as described herein. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region follows the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.
[0071] The “knob-into-hole” technique is described, for example, in U.S. Patent No. 5,731,168; No. 7,695,936; Ridgway et al., Prot Eng 9,617-621 (1996); and Carter, J Immunol Meth 248,7-15 (2001). Generally, the method involves introducing a ridge ("knob") at the interface of a first polypeptide and a corresponding cavity ("hole") at the interface of a second polypeptide, so that the ridge can be positioned within the cavity to promote heterodimerization and inhibit homodimerization. The ridge is constructed by replacing a smaller amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). Compensatory cavities of the same or similar size as the bulges are created at the interface of the second polypeptide by replacing a larger amino acid side chain with a smaller amino acid side chain (e.g., alanine or threonine). The bulges and cavities can be created, for example, by modifying the nucleic acid encoding the polypeptide by site-directed mutagenesis, or by peptide synthesis. In a specific embodiment, the knob modification includes the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification includes the amino acid substitutions T366S, L368A, and Y407V in the other of the two subunits of the Fc domain. In a further specific embodiment, the subunit of the Fc domain containing the knob modification additionally includes the amino acid substitution S354C, and the subunit of the Fc domain containing the hole modification additionally includes the amino acid substitution Y349C. The introduction of these two cysteine residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thereby further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).
[0072] The “region equivalent to the Fc region of immunoglobulins” is intended to include variants that, in addition to naturally occurring allele variants of the Fc region of immunoglobulins, have modifications that produce substitutions, additions, or deletions but do not substantially reduce the immunoglobulin’s ability to mediate effector functions (e.g., antibody-dependent cytotoxicity). For example, one or more amino acids may be deleted from the N-terminus or C-terminus of the Fc region of immunoglobulins without substantial loss of biological function. Such variants may be selected according to general rules known in the art to have the least effect on activity (see, for example, Bowie, JU et al., Science 247:1306-10 (1990)).
[0073] The term "effector function" refers to the biological activity attributed to the Fc region of an antibody, which varies with antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.
[0074] An "activated Fc receptor" is an Fc receptor that, after engagement by the Fc region of an antibody, triggers a signaling event that stimulates receptor-hosting cells to perform effector functions. Activated Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). A specific activated Fc receptor is human FcγRIIIa (see UniProt accession number P08637, version 141).
[0075] A "blocking" antibody or "antagonist" antibody is an antibody that inhibits or reduces the biological activity of the antigen to which it binds. In some embodiments, a blocking antibody or antagonist antibody substantially or completely inhibits the biological activity of the antigen. For example, the bispecific antibodies of the present invention block signaling through TGF-β and activin so as to inhibit the TGF-β / activin-Smad2 / 3 signaling pathway.
[0076] As used herein, “specific binding” means that binding is selective for an antigen and can be distinguished from undesirable or nonspecific interactions. The ability of an antigen-binding molecule to bind to a specific antigen can be measured through either enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) techniques (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)).
[0077] The terms "affinity" or "binding affinity," as used herein, refer to the total strength of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). The affinity of molecule X for its partner Y can generally be expressed by the dissociation constant (KD), which is the ratio of the dissociation and association rate constants (koff and kon, respectively). A specific method for measuring affinity is surface plasmon resonance (SPR). As used herein, the term "high affinity" of an antibody means that the antibody has a 10% affinity for its target antigen. -9 M or lower, especially 10 -10 This refers to having an M or lower Kd. The term "low affinity" for an antibody means that the antibody has 10 -8This refers to having M or a higher Kd. The term "reduced binding," as used herein, refers to a decrease in affinity for each interaction, for example, as measured by SPR. Conversely, "increased binding" refers to an increase in binding affinity for each interaction.
[0078] The terms “bispecific antibody comprising a first antigen-binding molecule that specifically binds to activin or an activin-related ligand and a second antigen-binding molecule that specifically binds to TGF-β,” “bispecific antibody that specifically binds to activin or an activin-related ligand and TGF-β,” and “bispecific antigen-binding molecule specific to activin or an activin-related ligand and TGF-β” are used interchangeably herein and refer to a bispecific antibody having the ability to bind to activin or an activin-related ligand and TGF-β with sufficient affinity to be useful as a diagnostic and / or therapeutic agent in targeting activin or an activin-related ligand and TGF-β.
[0079] The terms “anti-activin antibody” and “antibody containing an antigen-binding site that binds to activin” refer to an antibody that has the ability to bind to activin, particularly activin polypeptides expressed on the cell surface, with sufficient affinity to be useful in targeting activin as a diagnostic and / or therapeutic agent. In one embodiment, the degree of binding of an anti-activin antibody to unrelated non-activin proteins is lower than about 10% of the binding of the antibody to activin, as measured, for example, by radioimmunoassay (RIA) or flow cytometry (FACS) or by surface plasmon resonance assay using a biosensor system, such as the Biacore® system. In a particular embodiment, the antigen-binding molecule that binds to human activin is, for example, 10 -8 M~10 -13M has a KD value of binding affinity for binding to human activin. In one preferred embodiment, the KD value of each binding affinity is determined in a surface plasmon resonance assay using the extracellular domain (ECD) of human activin (activin-ECD) for activin binding affinity. The term “anti-activin antibody” also includes bispecific antibodies that have the ability to bind to activin and a second antigen.
[0080] The terms “anti-TGF-β antibody” and “antibody containing an antigen-binding site that binds to TGF-β” refer to an antibody that has the ability to bind to TGF-β, particularly TGF-β polypeptides expressed on the cell surface, with sufficient affinity to be useful in targeting TGF-β as a diagnostic and / or therapeutic agent. In one embodiment, the degree of binding of an anti-TGF-β antibody to unrelated non-TGF-β proteins is lower than about 10% of the binding of the antibody to TGF-β, as measured, for example, by radioimmunoassay (RIA) or flow cytometry (FACS) or by surface plasmon resonance assay using a biosensor system, such as the Biacore® system. In a particular embodiment, the antigen-binding molecule that binds to human TGF-β is, for example, 10 -8 M~10 -13 M has a KD value for binding affinity to human TGF-β. In one preferred embodiment, the KD value of each binding affinity is determined in a surface plasmon resonance assay using the extracellular domain (ECD) of human TGF-β (TGF-β-ECD) for TGF-β binding affinity. The term “anti-TGF-β antibody” also encompasses bispecific antibodies that have the ability to bind to TGF-β and a second antigen.
[0081] As used herein, the term "fusion protein" refers to a fusion polypeptide molecule comprising two or more genes that originally encoded separate proteins, wherein the components of the fusion protein are linked to each other by peptide bonds, either directly or through a peptide linker. As used herein, the term "fused" refers to components that are linked by peptide bonds, either directly or through one or more peptide linkers.
[0082] A "linker" is a molecule that joins two other molecules, either covalently or through ionic, van der Waals, or hydrogen bonds. For example, a nucleic acid molecule that hybridizes to one complementary sequence at the 5' end and to another complementary sequence at the 3' end, thereby joining two non-complementary sequences. A "cleavable linker" is a linker that can be cleaved or otherwise severed to separate two components that were connected by the cleavable linker. Cleavable linkers are generally cleaved by enzymes, typically peptidases, proteases, nucleases, and lipases, etc. Cleavable linkers may also be cleaved by environmental cues, such as changes in temperature, pH, salt concentration, etc.
[0083] As used herein, the term "peptide linker" refers to a peptide comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art or described herein. Suitable, non-immunogenic linker peptides include, for example, (G4S) n , (SG4) n or G4(SG4)n peptide linkers. "n" is generally a number from 1-10, typically 2-4.
[0084] "Pharmaceutical composition" refers to a composition suitable for medicinal use in animals. A pharmaceutical composition contains a pharmacologically effective amount of an activator and a pharmaceutically acceptable carrier. "Pharmacologically effective amount" refers to the amount of agent effective to produce the intended pharmacological result. "pharmaceutically acceptable carrier" refers to any of the standard pharmaceutical carriers, media, buffers, and excipients, e.g., phosphate-buffered saline solution, 5% dextrose aqueous solution, and emulsions, e.g., oil / water or water / oil emulsion, and various types of wetting agents and / or adjuvants. Suitable pharmaceutical carriers and formulations are listed in Remington's Pharmaceutical Sciences, 21st Ed. 2005, Mack Publishing Co, Easton. "pharmaceutically acceptable salt" refers to a salt that can be incorporated into a compound for medicinal use, e.g., metal salts (such as sodium, potassium, magnesium, calcium, etc.) and salts of ammonia or organic amines.
[0085] As used herein, “treatment” (and its grammatical variations, e.g., “treat” or “treating”) refers to a clinical intervention in an attempt to alter the natural course of a disease in the treated individual, which may be performed either preventively or during the course of a clinical pathological condition. The desired effects of treatment include, but are not limited to, prevention of the onset or recurrence of the disease, reduction of symptoms, reduction of any direct or indirect pathological consequences of the disease, prevention of metastasis, reduction of the rate of disease progression, remission or temporary relief of the disease state, and improved or better prognosis. As used herein, “reducing” a disease, disorder, or condition means reducing the severity and / or frequency of the symptoms of the disease, disorder, or condition. Furthermore, references to “treatment” herein include references to curative, palliative, and preventive treatments.
[0086] The terms “effective dose” or “therapeutic effective dose,” as used herein, refer to an amount of a compound or composition sufficient to treat a specified disorder, condition or disease, for example, to alleviate, reduce, and / or delay one or more of its symptoms. With respect to cancer or other undesirable cell proliferation, an effective dose includes an amount sufficient to (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, delay, slow to some extent, preferably halt, cancer cell infiltration into peripheral organs; (iv) inhibit tumor metastasis (i.e., slow to some extent, preferably halt); (v) inhibit tumor growth; (vi) prevent or delay tumor development and / or recurrence; and / or (vii) alleviate to some extent one or more of the symptoms associated with cancer. An effective dose may be administered in one or more doses.
[0087] The phrases “administer” or “cause to be administered” refer to the act of controlling and / or permitting the administration of the agent / compound in question to a patient, performed by a healthcare professional (e.g., a physician) or the person responsible for the patient’s medical care. Causing to be administered may involve a diagnosis and / or determination of an appropriate treatment regimen, as well as / or the prescription of a specific agent / compound for the patient. Such a prescription may include, for example, writing a prescription form and annotating a medical record. Where administration is described herein, “causing to be administered” is also assumed.
[0088] The terms “patient,” “individual,” and “subject” are interchangeable and may refer to mammals, preferably humans or non-human primates, but may also refer to domesticated mammals (e.g., dogs or cats), laboratory mammals (e.g., mice, rats, rabbits, hamsters, guinea pigs), and agricultural mammals (e.g., horses, cattle, pigs, sheep). In various embodiments, the patient may be a human being (e.g., adult males, adult females, adolescent males, adolescent females, boys, girls) under the care of a physician or other healthcare professional in an outpatient setting or other clinical setting, such as a hospital or psychiatric nursing facility. In various embodiments, the patient may include, but is not limited to, immunocompromised patients or patients with a weakened immune system, including patients with primary immunodeficiency, AIDS; patients with cancer; and transplant patients taking certain immunosuppressants; and patients with genetic disorders affecting the immune system (e.g., congenital agammaglobulinemia, congenital IgA deficiency). In various embodiments, patients have immunogenic cancers, including but not limited to bladder cancer, lung cancer, melanoma, and other cancers that have been reported to have a high rate of mutation (Lawrence et al., Nature, 499(7457):214-218, 2013).
[0089] The term "immunotherapy" includes treatments using depletion antibodies against specific tumor antigens; treatments using antibody-drug conjugates; treatments using agonists, antagonists, or blocking antibodies against costimulatory or coinhibitory molecules (immune checkpoints), e.g., CTLA-4, PD-1, OX-40, CD137, GITR, LAG3, TIM-3, SIRP, CD40, CD47, Siglec 8, Siglec 9, Siglec 15, TIGIT, and VISTA; treatments using bispecific T-cell engaging antibodies (BiTE®), e.g., blinatumomab; and biological response modifiers, e.g., IL-2, IL-12, IL-15, IL-21, GM-CSF, IFN-α, IFN-α. This refers to cancer treatments that include, but are not limited to, treatments involving the administration of N-β and IFN-γ; treatments using therapeutic vaccines, such as cypluce-T; treatments using Bacillus calmette-Guérin (BCG); treatments using dendritic cell vaccines or tumor antigen peptide vaccines; treatments using chimeric antigen receptor (CAR)-T cells; treatments using CAR-NK cells; treatments using tumor-infiltrating lymphocytes (TILs); treatments using adoptively transferred antitumor T cells (ex vivo expanding and / or TCR transgenic); treatments using TALL-104 cells; and treatments using immunostimulants, such as the Toll-like receptor (TLR) agonists CpG and imiquimod.
[0090] "Resistant or refractory cancer" refers to tumor cells or cancer that do not respond to previous anticancer therapies, including, for example, chemotherapy, surgery, radiotherapy, stem cell transplantation, and immunotherapy. Tumor cells may be resistant or refractory at the beginning of treatment, or may become resistant or refractory during treatment. Refractory tumor cells include tumors that do not respond at the start of treatment, or that initially respond for a short period but do not respond to treatment. Refractory tumor cells also include tumors that respond to treatment with anticancer therapy but do not respond to subsequent rounds of therapy. For the purposes of this invention, refractory tumor cells also include tumors that appear to be inhibited by treatment with anticancer therapy but recur within 5 years, possibly 10 years, or longer after treatment is discontinued. Anticancer therapy may be a chemotherapeutic agent alone, radiotherapy alone, targeted therapy alone, immunotherapy alone, surgery alone, or a combination thereof. For ease of description and not limited thereto, it is understood that refractory tumor cells are interchangeable with resistant tumors.
[0091] The term "polymer," as used herein, generally includes, but is not limited to, homopolymers; copolymers, such as block, graft, random, and alternating copolymers; and ternary copolymers; as well as blends and modifications thereof. Furthermore, unless otherwise specifically limited, the term "polymer" includes all possible geometric configurations of a material. These configurations include, but are not limited to, isotactic, syndiotactic, and random symmetries.
[0092] "Polynucleotides" refer to polymers composed of nucleotide units. Polynucleotides include naturally occurring nucleic acids, such as deoxyribonucleic acid ("DNA") and ribonucleic acid ("RNA"), as well as nucleic acid analogs. Nucleic acid analogs include those containing bases not naturally occurring, nucleotides involved in linking with other nucleotides besides naturally occurring phosphodiester bonds, or bases attached through linkages other than phosphodiester bonds. Therefore, nucleotide analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotryesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methylphosphonates, 2-O-methylribonucleotides, and peptide-nucleic acid (PNA). Such polynucleotides can be synthesized, for example, using automated DNA synthesizers. The term "nucleic acid" typically refers to large polynucleotides. The term "oligonucleotide" typically refers to short polynucleotides, generally about 50 nucleotides or fewer. When a nucleotide sequence is represented by a DNA sequence (i.e., A, T, G, C), it is understood that this also includes an RNA sequence in which "U" replaces "T" (i.e., A, U, G, C).
[0093] Conventional notation is used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5' end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5'-direction. The direction of nucleotide addition from 5' to 3' into a nascent RNA transcript is referred to as the transcription direction. The DNA strand having the same sequence as the mRNA is referred to as the "coding strand"; the sequence on the DNA strand having the same sequence as the mRNA transcribed from that DNA and located 5' relative to the 5' end of the RNA transcript is referred to as the "upstream sequence"; and the sequence on the DNA strand having the same sequence as the RNA and located 3' relative to the 3' end of the coding RNA transcript is referred to as the "downstream sequence".
[0094] "Complementary" refers to the topological compatibility or matching of the interacting surfaces of two polynucleotides. Therefore, two molecules can be described as complementary, and furthermore, the features of their contact surfaces are complementary to each other. A first polynucleotide is complementary to a second polynucleotide if the nucleotide sequence of the first polynucleotide is substantially identical to the nucleotide sequence of the polynucleotide binding partner of the second polynucleotide, or if the first polynucleotide can hybridize to the second polynucleotide under stringent hybridization conditions.
[0095] "Specific hybridization" or "selective hybridization" refers to the preferential binding, duplexing, or hybridization of a nucleic acid molecule to a particular nucleotide sequence under stringent conditions, given its presence in a complex mixture of DNA or RNA (e.g., a whole cell). The term "stringent conditions" refers to conditions under which a probe preferentially hybridizes to its target subsequence and to a lower degree, or not hybridizes at all, to other sequences. "Stringent hybridization" and "stringent hybridization conditions" in the context of nucleic acid hybridization experiments, such as Southern and Northern hybridization, are sequence-dependent and vary under different environmental parameters. Comprehensive guides on nucleic acid hybridization can be found in Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes, part I, chapter 2, “Overview of principles of hybridization and the strategy of nucleic acid probe assays”, Elsevier, NY; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3rd sup.rd ed., NY; and Ausubel et al., ed., Current Edition, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY.
[0096] Generally, highly stringent hybridization and washing conditions are selected to be approximately 5°C lower than the thermal melting point (Tm) for a particular sequence at a defined ionic strength and pH. Tm is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe (under defined ionic strength and pH). Very stringent conditions are selected to be equal to the Tm for a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleic acids with approximately 100 or more complementary residues on a filter in Southern or Northern blots is 50% formalin with 1 mg of heparin at 42°C, with hybridization performed overnight. An example of highly stringent washing conditions is 0.15 M NaCl, 72°C, for approximately 15 minutes. An example of stringent washing conditions is washing with 0.2 × SSC, 65°C, for 15 minutes. See Sambrook et al. for a description of SSC buffers. High-stringency washes may be preceded by low-stringency washes to remove background probe signals. For example, an exemplary medium-stringency wash for double helices with approximately 100 or more nucleotides is 1 × SSC, 45°C, 15 minutes. For example, an exemplary low-stringency wash for double helices with approximately 100 or more nucleotides is 4–6 × SSC, 40°C, 15 minutes. In general, a signal-to-noise ratio twice (or higher) than that observed for unrelated probes in a particular hybridization assay indicates the detection of specific hybridization.
[0097] A "primer" refers to a polynucleotide that has the ability to specifically hybridize to a designated polynucleotide template and provide a starting point for the synthesis of a complementary polynucleotide. Such synthesis occurs when the polynucleotide primer is placed under conditions that induce synthesis, i.e., in the presence of a nucleotide, a complementary polynucleotide template, and a polymerization agent, such as DNA polymerase. Primers are typically single-stranded, but may also be double-stranded. Primers are typically deoxyribonucleic acid, but a variety of synthetic and naturally occurring primers are useful for many applications. A primer is complementary to the template to which it is designed to hybridize in order to serve as a site for the initiation of synthesis, but does not need to reflect the exact sequence of the template. In such cases, the specific hybridization of the primer to the template depends on the stringency of the hybridization conditions. Primers can be labeled, for example, with a chromogenic, radioactive, or fluorescent moiety and used as a detectable moiety.
[0098] When used in relation to polynucleotides, "probe" refers to a polynucleotide that has the ability to specifically hybridize to a specified sequence of another polynucleotide. The probe specifically hybridizes to the target complementary polynucleotide, but does not need to reflect the exact complementary sequence of the template. In such cases, the specific hybridization of the probe to the target depends on the stringency of the hybridization conditions. The probe may be labeled with, for example, a pigment-generating, radioactive, or fluorescent moiety and used as a detectable moiety. In cases where the probe provides a starting point for the synthesis of the complementary polynucleotide, the probe can also be a primer.
[0099] A "vector" is a polynucleotide that can be used to introduce another nucleic acid, to which it is ligated, into a cell. One type of vector is a "plasmid," which refers to a linear or circular double-stranded DNA molecule to which an additional nucleic acid segment can be ligated. Another type of vector is a viral vector (e.g., replication-deficient retroviruses, adenoviruses, and adeno-associated viruses), to which an additional DNA segment can be introduced into the viral genome. Certain vectors have the ability to autonomously replicate in the host cell into which they are introduced (e.g., bacterial vectors containing bacterial origins of replication and episomatic mammalian vectors). Other vectors (e.g., non-episomatic mammalian vectors) are integrated into the host cell's genome upon introduction into the host cell and thereby replicate together with the host genome. An "expression vector" is a type of vector that can direct the expression of a selected polynucleotide.
[0100] A “regulatory sequence” is a nucleic acid that influences the expression (e.g., level, timing, or location) of the nucleic acid to which it is operably ligated. A regulatory sequence can exert its effect, for example, directly on the nucleic acid being regulated, or through the action of one or more other molecules (e.g., polypeptides that bind to the regulatory sequence and / or nucleic acid). Examples of regulatory sequences include promoters, enhancers, and other expression regulatory elements (e.g., polyadenylation signals). Further examples of regulatory sequences are described, for example, in Goeddel, 1990, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif., and Baron et al., 1995, Nucleic Acids Res. 23:3605-06. A nucleotide sequence is “operably ligated” to a regulatory sequence if the regulatory sequence influences the expression (e.g., level, timing, or location) of the nucleotide sequence.
[0101] "Host cell" refers to a cell that may be used to express the polynucleotides of this disclosure. A host cell may be a prokaryote, e.g., Escherichia coli, or a eukaryote, e.g., a single-celled eukaryote (e.g., yeast or other fungi), a plant cell (e.g., tobacco or tomato plant cell), an animal cell (e.g., human cell, monkey cell, hamster cell, rat cell, mouse cell, or insect cell), or a hybridoma. Typically, a host cell is a cultured cell that can be transformed or transfected with a nucleic acid encoding a polypeptide, which can then be expressed in the host cell. The term "recombinant host cell" may be used to describe a host cell that has been transformed or transfected with the nucleic acid to be expressed. A host cell may also be a cell that contains a nucleic acid but does not express the nucleic acid at the desired level until a regulatory sequence is introduced into the host cell so that it is operably linked to the nucleic acid. It is understood that the term host cell refers not only to a specific target cell but also to the offspring or potential offspring of such a cell. Because certain modifications may occur in subsequent generations, for example, due to mutation or environmental influences, such offspring may not actually be identical to the parent cells, but such offspring still fall within the scope of the term as used herein.
[0102] The term “isolated molecule” (where the molecule is, for example, a polypeptide or polynucleotide) is defined as a molecule that, for reasons of its origin or source of origin, (1) is not associated with naturally occurring components that are present with it in its native state, (2) substantially does not contain other molecules from the same species, (3) is expressed by cells from a different species, or (4) does not exist in nature. Therefore, a molecule that is chemically synthesized or expressed in a cellular system different from the cells from which the molecule originates naturally is “isolated” from its naturally occurring components. A molecule may also be made substantially free of naturally occurring components by isolation using purification techniques well known in the art. The purity or homogeneity of a molecule may be assayed by a number of means well known in the art. For example, the purity of a polypeptide sample may be assayed using polyacrylamide gel electrophoresis and gel staining for visualization of polypeptides using techniques well known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.
[0103] A protein or polypeptide is considered "substantially pure," "substantially homogeneous," or "substantially purified" if at least about 60% to 75% of the sample exhibits a single species of polypeptide. Polypeptides or proteins may be monomers or polymers. Substantially pure polypeptides or proteins typically constitute about 50%, 60%, 70%, 80%, or 90% w / w of a protein sample, more commonly about 95% w / w, and preferably more than 99% pure. The purity or homogeneity of a protein may be indicated by numerous means known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by staining the gel with stains known in the art to visualize a single polypeptide band. For certain purposes, higher resolution may be provided by using HPLC or other means known in the art for purification.
[0104] The terms “labeling” or “labeled,” as used herein, refer to the incorporation of another molecule into an antibody. In one embodiment, labeling is the incorporation of a detectable marker, e.g., a radiolabeled amino acid, or the attachment of a biotinyl moiety to a polypeptide that can be detected by a marked avidin (e.g., a streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetry). In another embodiment, the label or marker may be a therapeutic agent, e.g., a drug conjugate or a toxin. Various methods for labeling polypeptides and glycoproteins are known in the art and can be used. Examples of labeling for polypeptides are: radioisotopes or radionuclides (e.g., 3 H, 14 C, 15 N, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131I) Fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzyme labels (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by secondary reporters (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal-binding domains, epitope tags), magnetic agents (e.g., gadolinium chelate), toxins (e.g., pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracendione This includes, but is not limited to, dione, mitoxantrone, mitramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, as well as their analogs or homologs. In various embodiments, the labels are attached by spacer arms of varying lengths to reduce potential steric hindrance.
[0105] When used herein, the term "heterogeneous" refers to a composition or state that is neither native nor naturally occurring, for example, one that can be achieved by replacing an existing natural composition or state with one derived from another source. Similarly, the expression of a protein in an organism other than the organism in which it is naturally expressed constitutes a heterogeneous expression system and a heterogeneous protein.
[0106] It is understood that the aspects and embodiments of the disclosure described herein include aspects and embodiments that "consist of" and / or "essentially consist of".
[0107] References to values or parameters “about” in this specification include (and describe) variations directed toward the value or parameter itself. For example, a statement referring to “about X” includes a statement of “X.”
[0108] As used herein and in the appended claims, the singular “a,” “or,” and “the” refer to multiple subjects unless the context otherwise explicitly states. The aspects and variations of the disclosure described herein are understood to include aspects and variations consisting of and / or essentially consisting of.
[0109] Activin and activin-related ligands Activins, including activin A, activin B, and activin AB, as well as activin-related proteins, including myostatin (GDF-8) and GDF-11, mediate Smad2 / 3 signaling through the binding and activation of their high-affinity receptors, ActRIIA and ActRIIB, on the cell surface. Activins and related proteins play essential roles in regulating a wide range of biological activities, including mesoderm induction, cell differentiation, myogenesis, bone remodeling, hematopoiesis, fibrosis, and reproductive physiological functions. The secreted glycoprotein, follistatin (FST), binds to activins and activin-related ligands, negatively regulating their signaling activity.
[0110] In various embodiments, the bifunctional molecules of the present invention have the ability to bind to activin or activin-related ligands having an amino acid sequence selected from the group consisting of the amino acid sequences described in SEQ ID NOs: 1 to 9. Human ActRIIA-ECD ETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPP(Sequence ID 1) Human ActRIIB-ECD ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEV TYEPPPTAPT(Sequence ID 2) Human follistatin 315 GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW(Sequence ID 3) Human follistatin ΔHBS (modified follistatin) GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGQSCVVDQTGSPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW (Sequence ID 4) Human follistatin 288 GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCN (Sequence ID 5) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCEGDQDKRLHCYASWRNSSGTIELVKKGCWLDDINCYDRQECVATKENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT(Sequence ID 6) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCYGDKDKRRHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT(Sequence ID 7) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWDDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPT(Sequence ID 8) Modified Human ActRIIA ECD GAILGRSETQECLFYNANWELERTNQTGVEPCEGEKDKRLHCYATWRNISGSIEIVKKGCWLDDFNCYDRTDCVETEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS(Sequence ID 9)
[0111] In various embodiments, the polyspecific polypeptide molecule has the ability to bind to activin or activin-related ligands having an amino acid sequence selected from the group consisting of the amino acid sequences listed in Table 2: TIFF2023548399000003.tif68170
[0112] TGF-β ligand Transforming growth factor-beta (TGF-β), including TGF-β1, TGF-β2, and TGF-β3, mediates Smad2 / 3 signaling through its binding to and activation of high-affinity receptors TGFβRII and TGFβRIIB on the cell surface. TGF-β plays an essential role in regulating a wide range of biological activities, including immune function, cell proliferation and differentiation, epithelial-mesenchymal transition, fibrosis, hematopoiesis, myogenesis, bone remodeling, and cancer progression and metastasis. Elevated TGF-β levels and consequently increased Smad2 / 3 signaling have been linked to the pathogenesis and progression of many disease conditions, including cancer, anemia, bone metastases, osteopenia, fibrosis, pain, muscle loss, insulin resistance, chronic kidney disease, liver disease, and cardiovascular disease.
[0113] In various embodiments, the polyspecific polypeptide molecules of the present invention have the ability to bind to TGF-β ligands having an amino acid sequence selected from the group consisting of the amino acid sequences described in SEQ ID NOs: 18-21. Human TGF-β receptor II isoform 1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSD ECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEE YASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYM APEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK (Sequence No. 18) Human TGF-β receptor II-ECD isoform 1 (TGF-β RIIB-ECD) TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence ID 19) Human TGF-β receptor II isoform 2 (Sequence ID 20) Human TGF-β receptor II-ECD isoform 2 (TGF-β RIIA-ECD) TIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 21)
[0114] In various embodiments, the polyspecific polypeptide molecule has the ability to bind to a TGF-β ligand having an amino acid sequence selected from the group consisting of the amino acid sequences listed in Table 3: TIFF2023548399000004.tif56170
[0115] Activin and / or TGF-β antibody and antibody fragments Methods for generating novel antibodies that bind to activin or activin-related ligands and / or TGF-β ligands and / or receptors are known to those skilled in the art. For example, a method for generating monoclonal antibodies that specifically bind to activin or activin-related ligands and / or TGF-β ligands may include administering an immunogenic composition containing activin or activin-related ligands and / or TGF-β ligands in an amount effective enough to stimulate a detectable immune response to a mouse, obtaining antibody-producing cells from the mouse (e.g., cells from the spleen), fusing the antibody-producing cells with myeloma cells to obtain antibody-producing hybridomas, and testing the antibody-producing hybridomas to identify hybridomas that produce monoclonal antibodies that specifically bind to activin or activin-related ligands and / or TGF-β ligands. Once hybridomas are obtained, they can be optionally propagated in cell culture under conditions in which hybridoma-derived cells produce monoclonal antibodies that specifically bind to activin or activin-related ligands and / or TGF-β ligands. Monoclonal antibodies may be purified from cell cultures. Various different techniques are then available to test antigen / antibody interactions and identify particularly desirable antibodies.
[0116] Other suitable methods are available for producing or isolating antibodies of the required specificity, including, for example, selecting recombinant antibodies from a library or relying on immunization of transgenic animals (e.g., mice) capable of producing a complete repertoire of human antibodies. See, for example, Jakobovits et al., Proc. Natl. Acad. Sci. (USA), 90:2551-2555, 1993; Jakobovits et al., Nature, 362:255-258, 1993; Lonberg et al., U.S. Patent No. 5,545,806; and Surani et al., U.S. Patent No. 5,545,807.
[0117] Antibodies can be manipulated in numerous ways. Antibodies can be produced as single-chain antibodies (including small modular immunopharmaceuticals or SMIPs®), Fab and F(ab')2 fragments, etc. Antibodies can be humanized, chimeric, deimmunized, or fully human antibodies. Numerous publications describe many types of antibodies and methods for manipulating such antibodies. See, for example, U.S. Patents 6,355,245; 6,180,370; 5,693,762; 6,407,213; 6,548,640; 5,565,332; 5,225,539; 6,103,889; and 5,260,203.
[0118] Chimeric antibodies can be produced by recombinant DNA techniques known in the art. For example, the gene encoding the Fc constant region of a mouse (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove the mouse Fc encoding region and replaced with an equivalent portion of the gene encoding the human Fc constant region (Robinson et al., International Publication PCT / US86 / 02269; Akira, et al., European Patent Application No. 184,187; Taniguchi, M., European Patent Application No. 171,496; Morrison et al., European Patent Application No. 173,494; Neuberger et al., International Publication 86 / 01533; Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application No. 125,023; Better et al., Science, 240:1041-1043, 1988; Liu et al.,Proc.Natl.Acad.Sci.(USA),84:3439-3443,1987;Liu et al.,J.Immunol.,139:3521-3526,1987;Sun et al.,Proc.Natl.Acad.Sci.(USA),84:214-218,1987;Nishimura et al. al., Canc. Res., 47:999-1005, 1987; Wood et al., Nature, 314:446-449, 1985; and Shaw et al., J. Natl Cancer Inst., 80:1553-1559, 1988).
[0119] Methods for humanizing antibodies have been described in the Art. In some embodiments, the humanized antibody has one or more amino acid residues introduced from a non-human source in addition to the non-human CDR. Humanization can essentially be carried out by substituting the hypervariable region sequence with the corresponding sequence of the human antibody, according to the method of Winter and collaborators (Jones et al., Nature, 321:522-525, 1986; Riechmann et al., Nature, 332:323-327, 1988; Verhoeyen et al., Science, 239:1534-1536, 1988). Thus, such a “humanized” antibody is a chimeric antibody (U.S. Patent No. 4,816,567) in which substantially less of the intact human variable region is replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and, in some cases, some framework region residues are replaced with residues from similar sites in rodent antibodies.
[0120] Queen et al.'s U.S. Patent No. 5,693,761 discloses a refinement in Winter et al. for humanizing antibodies, based on the premise that avidity loss can be attributed to problems in structural motifs in the humanized framework that interfere with the folding of the CDR into a binding-enabled conformation found in the mouse antibody due to steric or other chemical incompatibility. To address this problem, Queen instructs the use of a human framework sequence in a linear peptide sequence that is closely homologous to the framework sequence of the mouse antibody to be humanized. Thus, Queen's method focuses on comparing framework sequences across species. Typically, all available human variable region sequences are compared to a specific mouse sequence, and the percentage of identity between the corresponding framework residues is calculated. The human variable region with the highest percentage is selected to provide a framework sequence for the humanization project. Queen also instructs that it is important to retain certain amino acid residues from the mouse framework that are essential to supporting the CDR in the binding-enabled conformation in the humanized framework. Potential essentiality is assessed from molecular models. Candidate residues for retention are typically those adjacent to a CDR in a linear sequence, or physically within 6 Å of any CDR residue.
[0121] Another method for humanizing antibodies, referred to as "framework shuffling," relies on generating a combinatorial library containing non-human CDR variable regions fused in-frame to a pool of individual human germline frameworks (Dall'Acqua et al., Methods, 36:43, 2005). The library is then screened to identify clones encoding humanized antibodies that retain good binding.
[0122] Methods for producing fully human antibodies have been described in the Art. For example, a method for producing an anti-activin antibody or its antigen-binding fragment comprises the steps of synthesizing a library of human antibodies on phages, screening the library using an activin polypeptide or its antibody-binding moiety, isolating phages that bind to the activin polypeptide, and obtaining antibodies from the phages. Another example is a method for preparing a library of antibodies for use in phage display technology, comprising the steps of immunizing a non-human animal containing a human immunoglobulin locus with an activin polypeptide or its antigenic moiety to induce an immune response, extracting antibody-producing cells from the immunized animal; isolating RNA encoding the heavy and light chains of the antibody of the present invention from the extracted cells, reverse transcribing the RNA to produce cDNA, amplifying the cDNA using primers, and inserting the cDNA into a phage display vector to express the antibody on phages. The recombinant anti-activin antibody of the present invention may be obtained in this manner.
[0123] The recombinant human anti-activin and / or TGF-β antibodies of the present invention may also be isolated by screening a recombinant combinatorial antibody library. Preferably, the library is prepared from mRNA isolated from B cells. L and V HThis is an scFv phage display library generated using cDNA. Methods for preparing and screening such libraries are known in the art. Kits for generating phage display libraries are commercially available (e.g., Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and Stratagene SurfZAP® phage display kit, catalog no. 240612). Other methods and reagents may be used in the generation and screening of antibody display libraries (e.g., U.S. Publication No. 5,223,409; PCT International Publication No. 92 / 18619, International Publication No. 91 / 17271, International Publication No. 92 / 20791, International Publication No. 92 / 15679, International Publication No. 93 / 01288, International Publication No. 92 / 01047, International Publication No. 92 / 09690; Fuchs et al., Bio / Technology, 9:1370-1372 (1991); Hay et al., Hum.Antibod.Hybridomas, 3:81-85, 1992; Huse et al., Science, 246:1275-1281, 1989; McCafferty et al. al.,Nature,348:552-554,1990;Griffiths et al.,EMBO J.,12:725-734,1993;Hawkins et al.,J.Mol.Biol.,226:889-896,1992;Clackson et al.,Nature,352:624-628,1991;Gram et al. al., Proc. Natl. Acad. Sci. (USA), 89:3576-3580, 1992; Garrad et al., Bio / Technology, 9: 1373-1377, 1991; Hoogenboom et al., Nuc. Acid Res., 19: 4133-4137, 1991; and Barbas et al. See al., Proc. Natl. Acad. Sci. (USA), 88:7978-7982, 1991; all are incorporated herein by reference).
[0124] Human antibodies are also produced by immunizing non-human transgenic animals, such as XenoMouse® animals (Abgenix, Inc. / Amgen, Inc.--Fremont, Calif.), which contain some or all of the human immunoglobulin heavy and light chain loci in their genome, with human IgE antigens. XenoMouse® mice are engineered mouse strains that contain large fragments of the human immunoglobulin heavy and light chain loci and are deficient in mouse antibody production. See, for example, Green et al., Nature Genetics, 7:13-21, 1994 and U.S. Patents 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091,001, 6,114,598, 6,130,364, 6,162,963 and 6,150,584. XenoMouse® mice produce an adult-like human repertoire of fully human antibodies and generate antigen-specific human antibodies. In some embodiments, XenoMouse® mice contain approximately 80% of the human antibody V gene repertoire through the introduction of megabase-sized germline fragments of human heavy chain and kappa light chain loci in yeast artificial chromosomes (YACs). In other embodiments, XenoMouse® mice further contain substantially all human lambda light chain loci. See Mendez et al., Nature Genetics, 15:146-156, 1997; Green and Jakobovits, J.Exp.Med., 188:483-495, 1998; and International Publication No. 98 / 24893. In one embodiment, the present invention provides a method for producing anti-activin and / or TGF-β antibodies from non-human, non-mouse animals by immunizing non-human transgenic animals containing human immunoglobulin loci with activin and / or TGF-β polypeptides. Such animals can be produced using the methods described in the literature referenced above.
[0125] Anti-activin antibodies In various embodiments of the present invention, the anti-activin antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 10: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWIIPYNGNTNSAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARDRDYGVNYDAFDIWGQG TMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNVYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 10) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 11: SYEVTQAPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 11) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 10 and the light chain amino acid sequence described in SEQ ID NO: 11; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 12: QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWIIPYNGNTNSAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARDRDYGVNYDAFDIWGQGTMVTVSS(Sequence ID 12) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 13: SYEVTQAPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL(Sequence ID 13) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 12 and the light chain variable region amino acid sequence described in SEQ ID NO: 13. It is an anti-activin A antibody.
[0126] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs: 10, 11, 12, or 13; and the antibody specifically binds to human activin A.
[0127] In various embodiments of the present invention, the anti-activin antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 14: QVQLQESGPGLVKPSETLSLTTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDI WGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP PCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 14) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 15: EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 15) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 14 and the light chain amino acid sequence described in SEQ ID NO: 15; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 16: QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS (Sequence ID 16) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 17: EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (Sequence ID 17) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 16 and the light chain variable region amino acid sequence described in SEQ ID NO: 17. It is an anti-activin A antibody.
[0128] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity to the amino acid sequence described in SEQ ID NOs: 14, 15, 16, or 17; and the antibody specifically binds to human activin A.
[0129] Anti-TGF-β antibody In various embodiments of the present invention, the anti-TGF-β antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 22: QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP SCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(Sequence ID 22) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 23: ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 23) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 22 and the light chain amino acid sequence described in SEQ ID NO: 23; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 24: QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS(Sequence ID 24) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 25: ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK (Sequence ID 25) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 24 and the light chain variable region amino acid sequence described in SEQ ID NO: 25. It is an anti-TGF-β antibody.
[0130] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs. 22, 23, 24, or 25; and the antibody specifically binds to human TGF-β.
[0131] PD-1, PD-L1, and CTLA-4 ligands Numerous immune checkpoint protein antigens have been reported to be expressed on various immune cells, including, for example, SIRP (expressed on macrophages, monocytes, and dendritic cells), CD47 (highly expressed on tumor cells and other cell types), VISTA (expressed on monocytes, dendritic cells, B cells, and T cells), and CD152 (expressed on activated CD8+ T cells and CD4+ T cells). This includes CD279 (expressed on tumor-infiltrating lymphocytes and expressed on activated T cells (both CD4 and CD8), regulatory T cells, activated B cells, activated NK cells, anergistic T cells, monocytes, and dendritic cells), CD274 (expressed on T cells, B cells, dendritic cells, macrophages, vascular endothelial cells, and pancreatic islet cells), and CD223 (expressed on activated T cells, regulatory T cells, anergistic T cells, NK cells, NKT cells, and plasmacytoid dendritic cells) (see, for example, Pardoll, D., Nature Reviews Cancer, 12:252-264, 2012). Antibodies that bind to antigens determined to be immune checkpoint proteins are known to those skilled in the art.For example, various anti-CD276 antibodies have been described in the art (see, for example, U.S. Patent Publication No. 20120294796 (Johnson et al) and the references therein); various anti-CD272 antibodies have been described in the art (see, for example, U.S. Patent Publication No. 20140017255 (Mataraza et al) and the references therein); various anti-CD152 / CTLA-4 antibodies have been described in the art (see, for example, U.S. Patent Publication No. 20130136749 (Korman et al) and the references therein); various anti-LAG-3 / CD223 antibodies have been described in the art (see, for example, U.S. Patent Publication No. 20110150892 (Thudium et al) and the references therein); and various anti-CD279 (PD-1) antibodies have been described in the art (see, for example, U.S. Patent No. 7,488,802 (Collins et al)). See references therein); various anti-CD274 (PD-L1) antibodies have been described in the Art (e.g., U.S. Patent Application Publication No. 20130122014 (Korman et al) and references therein); various anti-TIM-3 antibodies have been described in the Art (e.g., U.S. Patent Application Publication No. 20140044728 (Takayanagi et al) and references therein); and various anti-B7-H4 antibodies have been described in the Art (e.g., U.S. Patent Application Publication No. 20110085970 (Terrett et al) and references therein); and various anti-TIGIT antibodies have been described in the Art (e.g., U.S. Patent Application Publication No. 20180169239A1 (Grogan) and references therein). Each of these references is incorporated herein by reference in whole due to the specific antibodies and sequences taught therein.In various embodiments, the bifunctional, multispecific antagonist molecule has the ability to bind to immune checkpoint protein ligands selected from the group consisting of, but not limited to, CD279 (PD-1), CD274 (PDL-1), CD276, CD272, CD152, CD223 (LAG-3), CD40, SIRPα, CD47, OX-40, GITR, ICOS, CD27, 4-1BB, TIM-3, B7-H3, B7-H4, TIGIT, and VISTA.
[0132] In various embodiments, the bifunctional, multispecific antagonist molecule has the ability to bind to a PD-1 ligand, a PD-L1 ligand, or a CTLA-4 ligand having an amino acid sequence selected from the group consisting of the amino acid sequences listed in Table 4: TIFF2023548399000005.tif56170
[0133] Anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies In various embodiments of the present invention, the anti-PD-1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 26: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQG TTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 26) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 27: EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 27) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 26 and the light chain amino acid sequence described in SEQ ID NO: 27; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 28: QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS(Sequence ID 28) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 29: EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK (Sequence ID 29) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 28 and the light chain variable region amino acid sequence described in SEQ ID NO: 29. It is an anti-PD-1 antibody.
[0134] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs. 26, 27, 28, or 29; and the antibody specifically binds to human PD-1.
[0135] In various embodiments of the present invention, the anti-PD-1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 30: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPA PEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 30) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 31: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 31) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 30 and the light chain amino acid sequence described in SEQ ID NO: 31; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 32: QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS (Sequence ID 32) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 33: EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK(Sequence ID 33) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 32 and the light chain variable region amino acid sequence described in SEQ ID NO: 33. It is an anti-PD-1 antibody.
[0136] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs. 30, 31, 32, or 33; and the antibody specifically binds to human PD-1.
[0137] In various embodiments of the present invention, the anti-PD-1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 38: EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYW GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALH NHYTQKSLSLSLGK(Sequence ID 38) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 39: DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 39) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 38 and the light chain amino acid sequence described in SEQ ID NO: 39; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 40: EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS (Sequence No. 40) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 41: DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR(Sequence ID 41) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 40 and the light chain variable region amino acid sequence described in SEQ ID NO: 41. It is an anti-PD-1 antibody.
[0138] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs: 38, 39, 40, or 41; and the antibody specifically binds to human PD-1.
[0139] In various embodiments of the present invention, the anti-PD-1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 42: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(Sequence ID 42) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 43: QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(Sequence ID 43) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 42 and the light chain amino acid sequence described in SEQ ID NO: 43; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 44: EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS (Sequence ID 44) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in SEQ ID NO: 45: QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL(Sequence ID 45) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 44 and the light chain variable region amino acid sequence described in SEQ ID NO: 45. It is an anti-PD-1 antibody.
[0140] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity to the amino acid sequence described in SEQ ID NOs. 42, 43, 44, or 45; and the antibody specifically binds to human PD-1.
[0141] In various embodiments of the present invention, the anti-CTLA-4 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 34: QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 34) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 35: EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 35) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 34 and the light chain amino acid sequence described in SEQ ID NO: 35; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 36: QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS (Sequence No. 36) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 37: EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (Sequence ID 37) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 36 and the light chain variable region amino acid sequence described in SEQ ID NO: 37. It is an anti-CTLA-4 antibody.
[0142] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs: 34, 35, 36, or 37; and the antibody specifically binds to human CTLA-4.
[0143] In various embodiments of the present invention, the anti-PD-L1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 46: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 46) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 47: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 47) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 46 and the light chain amino acid sequence described in SEQ ID NO: 47; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 48: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (Sequence No. 48) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 49: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK (Sequence ID 49) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 48 and the light chain variable region amino acid sequence described in SEQ ID NO: 49. It is an anti-PD-L1 antibody.
[0144] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprises a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity to the amino acid sequence described in SEQ ID NOs. 46, 47, 48, or 49; and the antibody specifically binds to human PD-L1.
[0145] In various embodiments of the present invention, the anti-PD-L1 antibody is a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 50: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 50) Human antibodies or antigen-binding fragments containing the light chain amino acid sequence described in Sequence ID No. 51: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 51) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain amino acid sequence described in SEQ ID NO: 50 and the light chain amino acid sequence described in SEQ ID NO: 51; Human antibodies or antigen-binding fragments containing the heavy chain variable region amino acid sequence described in Sequence ID No. 52: EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS(Sequence ID 52) Human antibodies or antigen-binding fragments containing the light chain variable region amino acid sequence described in Sequence ID No. 53: EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK (Sequence ID 53) Alternatively, a human antibody or antigen-binding fragment containing the heavy chain variable region amino acid sequence described in SEQ ID NO: 52 and the light chain variable region amino acid sequence described in SEQ ID NO: 53. It is an anti-PD-L1 antibody.
[0146] In various embodiments, the present invention provides an antibody comprising a heavy chain, a light chain, or both a heavy chain and a light chain; a heavy chain variable region, a light chain variable region, or both a heavy chain variable region and a light chain variable region; the heavy chain, light chain, heavy chain variable region, or light chain variable region comprising a sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least about 99% identity with the amino acid sequence described in SEQ ID NOs. 50, 51, 52, or 53; and the antibody specifically binds to human PD-L1.
[0147] multispecific antagonist molecules In one embodiment, the present invention provides a novel polypeptide-based bifunctional antagonist molecule specifically designed to simultaneously neutralize activin signaling and TGF-β signaling in a potent manner, and comprising a first antigen-binding molecule that specifically binds to an activin ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand. In various embodiments, the polyspecific antagonist molecule comprises an isolated antibody or its antigen-binding fragment that specifically binds to activin, and an isolated antibody or its antigen-binding fragment that specifically binds to a TGF-β ligand. Importantly, these polyspecific antagonists also offer advantageous properties, such as productivity, stability, binding affinity, biological activity, specific targeting of certain cells, targeting efficiency, and reduced toxicity.
[0148] Exemplary multispecific antagonist molecules In various embodiments, the bifunctional antagonist molecule of the present invention is selected from the group of molecules including the designed and fusion partners listed in Table 5: TIFF2023548399000006.tif158170
[0149] In various embodiments, the multispecific antagonist molecules of the present invention, which are specifically designed to simultaneously neutralize activin signaling and TGF-β signaling in a potent manner, and which include a first antigen-binding molecule that specifically binds to an activin ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand, are selected from the group of molecules listed in Table 6: TIFF2023548399000007.tif98170
[0150] Bifunctional, multispecific antagonist molecule In another embodiment, the present invention provides novel polypeptide-based bifunctional, multispecific antagonist molecules specifically designed to simultaneously inhibit TGF-β, activin, and T-cell immune checkpoints (including PD1, PD-L1, or CTL4). In various embodiments, the bifunctional, multispecific antagonist molecule is a bifunctional, multispecific molecule comprising a first antigen-binding molecule ("activin-binding polypeptide") that specifically binds to an activin ligand or activin-related ligand, a second antigen-binding molecule ("TGF-β-binding polypeptide") that specifically binds to a TGF-β ligand, and a third antigen-binding molecule ("PD-1 / PD-L1 / CTLA-4-binding polypeptide") that specifically binds to any of the PD-1 ligand, PD-L1 ligand, or CTLA-4 ligand. Importantly, these bifunctional, multispecific antagonists also offer advantageous properties, such as productivity, stability, binding affinity, biological activity, specific targeting of certain cells, targeting efficiency, and reduced toxicity.
[0151] Exemplary bifunctional, multispecific antagonist molecules In various embodiments, the bifunctional, multispecific antagonist molecules of the present invention are selected from the group of molecules including the designed and fusion partners listed in Tables 7 and 8: TIFF2023548399000008.tif156170TIFF2023548399000009.tif230170TIFF2023548399000010.tif238170 TIFF2023548399000011.tif235170TIFF2023548399000012.tif147170TIFF2023548399000013.tif170170
[0152] Linker In various embodiments, a first antigen-binding molecule that specifically binds to activin or an activin-related ligand is attached to a second antigen-binding molecule that specifically binds to a TGF-β ligand by a linker and / or hinge-linker peptide. The linker or hinge-linker may be an artificial sequence of amino acids between 5, 10, 15, 20, 30, 40 or more that exhibits an α-helix conformation, or it may be relatively devoid of secondary structure.
[0153] Peptide linkers provide covalent linkage between protein domains as well as additional structural and / or spatial flexibility. As is known in the art, peptide linkers contain flexible amino acid residues, such as glycine and serine. In various embodiments, peptide linkers may contain 1 to 100 amino acids. In various embodiments, the spacer may contain the motif GGGSGGGS (SEQ ID NO: 131). In other embodiments, the linker may contain the motif GGGGS (SEQ ID NO: 134)n, where n is an integer from 1 to 10. In other embodiments, the linker may also contain amino acids other than glycine and serine. In another embodiment, the linker may contain other protein motifs, including but not limited to α-helix conformation sequences, such as AEAAAKEAAAKEAAAKA (SEQ ID NO: 129). In various embodiments, the length and composition of the linker may be tuned to optimize developability, including but not limited to activity, expression level, and aggregation tendency. In another embodiment, the peptide linker may be a simple chemical bond, such as an amide bond (e.g., by chemical conjugation of PEG).
[0154] Exemplary peptide linkers are provided in Table 9: TIFF2023548399000014.tif112170
[0155] Polynucleotides In another embodiment, the Disclosure provides isolated nucleic acid molecules comprising polynucleotides encoding the polyspecific or bifunctional polyspecific antagonist molecules of the Disclosure. The nucleic acid of interest may be single-stranded or double-stranded. Such nucleic acids may be DNA or RNA molecules. DNA includes, for example, cDNA, genomic DNA, synthetic DNA, PCR-amplified DNA, and combinations thereof. Genomic DNA encoding the polyspecific or bifunctional polyspecific antagonist molecules can be obtained from genomic libraries available for a number of species. Synthetic DNA can be obtained by the chemical synthesis of overlapping oligonucleotide fragments, followed by the assembly of fragments to reconstruct parts or all of the coding region and adjacent sequences. RNA can be obtained from prokaryotic expression vectors that direct high levels of mRNA synthesis, for example, vectors using the T7 promoter and RNA polymerase. cDNA can be obtained from libraries prepared from mRNA isolated from various tissues expressing the polyspecific or bifunctional polyspecific antagonist molecules. The DNA molecules of the Disclosure include, in addition to the full-length gene, its polynucleotides and fragments. The full-length gene may also include a sequence encoding an N-terminal signal sequence.
[0156] In various embodiments, the isolated nucleic acid molecule comprises a polynucleotide described herein and further comprises a polynucleotide encoding at least one heterologous protein described herein. In various embodiments, the nucleic acid molecule further comprises a polynucleotide encoding a linker or hinge linker described herein.
[0157] In various embodiments, the recombinant nucleic acids of this disclosure may be operably ligated to one or more regulatory nucleotide sequences in the expression of a polyspecific or bifunctional polyspecific antagonist molecule. Thus, the term regulatory sequence includes promoters, enhancers, and other expression regulatory elements. Exemplary regulatory sequences are described in Goeddel; Gene Expression Technology: Methods in Enzymology, Academic Press, San Diego, Calif. (1990). Typically, the one or more regulatory nucleotide sequences may include, but are not limited to, promoter sequences, leader or signal sequences, ribosome binding sites, transcription start and termination sequences, translation start and termination sequences, and enhancer or activator sequences. Constitutive or inducible promoters, as known in the art, are assumed by this disclosure. The promoter may be a naturally occurring promoter or a hybrid promoter combining elements of one or more promoters. Expression constructs may reside in cells on episomes, e.g., plasmids, or expression constructs may be inserted into chromosomes. In various embodiments, the expression vector contains a selection marker gene to enable the selection of transformed host cells. The selection marker gene is well known in the art and varies with the host cell used.
[0158] In another aspect of this disclosure, the nucleic acid of interest comprises a nucleotide sequence encoding a polyspecific or bifunctional polyspecific antagonist molecule and is provided in an expression vector operably ligated to at least one regulatory sequence. The term “expression vector” refers to a plasmid, phage, virus, or vector for expressing a polypeptide from a polynucleotide sequence. Suitable vectors for expression in host cells are readily available, and the nucleic acid molecule is inserted into the vector using standard recombinant DNA techniques. Such vectors may include a variety of expression regulatory sequences that control the expression of the DNA sequence, which can be used in these vectors to express the DNA sequence encoding a polyspecific or bifunctional polyspecific antagonist molecule when operably ligated to the DNA sequence. Such useful expression regulatory sequences include, for example, the early and late promoters of SV40, the tet promoter, the earliest promoters of adenovirus or cytomegalovirus, the RSV promoter, the lac system, the trp system, the TAC or TRC system, the T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, regulatory regions for fd coat proteins, promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, acid phosphatases, such as the promoter of PhoS, the promoter of the yeast α junction factor, the polyhedron promoter of the baculovirus system, and other sequences known to regulate the expression of genes in prokaryotic or eukaryotic cells or their viruses, as well as various combinations thereof. It should be understood that the design of expression vectors may depend on factors such as the selection of the host cell to be transformed and / or the type of protein whose expression is desired. Furthermore, the copy number of the vector, the ability to control the copy number and expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.
[0159] The recombinant nucleic acids of this disclosure may be prepared by ligating a cloned gene or portion thereof into a vector suitable for expression in prokaryotic cells, eukaryotic cells (yeast, birds, insects, or mammals), or both. Expression media for the preparation of recombinant polyspecific or bifunctional polyspecific antagonist molecules include plasmids and other vectors. For example, suitable vectors include plasmids of the type for expression in prokaryotic cells, e.g., Escherichia coli: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids, and pUC-derived plasmids.
[0160] Some mammalian expression vectors contain both a prokaryotic sequence to promote vector replication in bacteria and one or more eukaryotic transcription units expressed in eukaryotic cells. pcDNAI / amp, pcDNAI / neo, pRc / CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo, and pHyg-derived vectors are examples of mammalian expression vectors suitable for eukaryotic cell transfection. Some of these vectors have been modified with sequences from bacterial plasmids, e.g., pBR322, to promote replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses, e.g., bovine papillomavirus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived, and p205) may be used for transient protein expression in eukaryotic cells. Examples of other viral (including retrovirus) expression systems can be found in the following description of gene therapy delivery systems. Various methods used in plasmid preparation and host organism transformation are well known in the art. For general recombination procedures, as well as other suitable expression systems for both prokaryotic and eukaryotic cells, see Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press, 1989), Chapters 16 and 17. In some cases, it may be desirable to express recombinant polypeptides using baculovirus expression systems. Examples of such baculovirus expression systems include pVL-derived vectors (e.g., pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (e.g., pAcUW1), and pBlueBac-derived vectors (e.g., B-gal-containing pBlueBac III).
[0161] In various embodiments, vectors are designed for the production of target multispecific or bifunctional multispecific antagonist molecules in CHO cells, such as the Pcmv-Script vector (Stratagene, La Jolla, Calif.), the pcDNA4 vector (Invitrogen, Carlsbad, Calif.), and the pCI-neo vector (Promega, Madison, Wis.). As is evident, target gene constructs can be used to induce the expression of target multispecific or bifunctional multispecific antagonist molecules in cells propagated in culture, for example, to produce proteins, including fusion proteins or variant proteins, for purification.
[0162] Therefore, this disclosure further relates to methods for producing the polyspecific or bifunctional polyspecific antagonist molecule of interest. For example, host cells transfected with an expression vector encoding the polyspecific or bifunctional polyspecific antagonist molecule can be cultured under appropriate conditions to allow expression of the bifunctional antagonist molecule to occur. The polyspecific or bifunctional polyspecific antagonist molecule may be secreted and isolated from a mixture of cells and a medium containing the polyspecific or bifunctional polyspecific antagonist molecule. Alternatively, the polyspecific or bifunctional polyspecific antagonist molecule may be retained in the cytoplasm or in a membrane fraction, the cells may be harvested and lysed, and the protein isolated. The cell culture comprises host cells, medium, and other by-products. Suitable media for cell culture are well known in the art.
[0163] The polypeptides and proteins of this disclosure may be purified according to protein purification techniques well known to those skilled in the art. These techniques involve, at one level, coarse fractionation of proteinaceous and nonproteinaceous fractions. Once the peptides or polypeptides have been isolated from other proteins, the peptides or polypeptides of interest may be further purified using chromatography and electrophoresis techniques to achieve partial or complete purification (or purification to homogeneity). The terms “isolated polypeptide” or “purified polypeptide,” as used herein, are intended to mean a composition in which the polypeptide has been purified to any degree compared to its naturally occurring state and is isolated from other components. A purified polypeptide therefore also means the polypeptide that has been freed from the environment in which it may naturally exist. Generally, “purified” refers to a polypeptide composition that has been subjected to fractionation to remove various other components and substantially retains its expressed biological activity. When the term “substantially purified” is used, this designation refers to a peptide or polypeptide composition in which the polypeptide or peptide forms the main component of the composition, for example, about 50%, about 60%, about 70%, about 80%, about 85%, or about 90% or more of the proteins in the composition.
[0164] Various techniques suitable for use in purification are well known to those skilled in the art. These include, for example, precipitation using ammonium sulfate, PEG, and antibodies (immunoprecipitation) or by thermal denaturation followed by centrifugation; chromatography, such as affinity chromatography (protein-A column), ion exchange, gel filtration, reversed phase, hydroxyl apatite, hydrophobic interaction chromatography; isoelectric focusing; gel electrophoresis; and combinations of these techniques. As is generally known in the art, the order in which various purification steps are performed may be changed or certain steps may be omitted, but this is still considered to result in a suitable method for preparing substantially purified polypeptides.
[0165] Pharmaceutical composition In another embodiment, the disclosure provides a pharmaceutical composition comprising an isolated polyspecific or bifunctional polyspecific antagonist molecule mixed with a pharmaceutically acceptable carrier. Such pharmaceutically acceptable carriers are well known, understood and extensively described to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Edition, edited by Argennaro, Mack Publishing Company, 1990). The pharmaceutically acceptable carrier may be included, for example, for the purpose of modifying, maintaining, or preserving the pH, volumetric osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or permeation of the composition. Such a pharmaceutical composition may affect the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the polypeptide.Suitable pharmaceutically acceptable carriers include amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (e.g., boric acid, bicarbonate, Tris-HCl, citric acid, phosphoric acid, or other organic acids); fillers (e.g., mannitol or glycine); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)); complexing agents (e.g., caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (e.g., glucose, mannose, or dextrin); proteins (e.g., serum albumin, gelatin, or immunoglobulin); colorants; flavoring agents and diluents; emulsifiers; hydrophilic polymers (e.g., polyvinylpyrrolidone) This includes, but is not limited to, low molecular weight polypeptides; salt-forming counterions (e.g., sodium); preservatives (e.g., benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide); solvents (e.g., glycerin, propylene glycol, or polyethylene glycol); sugar alcohols (e.g., mannitol or sorbitol); suspending agents; surfactants or wetting agents (e.g., Pluronic acid, PEG, sorbitan esters, polysorbates, e.g., polysorbate 20, polysorbate 80, Triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancers (sucrose or sorbitol); tonicity enhancers (e.g., alkali metal halides (preferably sodium or potassium chloride, mannitol, sorbitol); delivery media; diluents; excipients and / or pharmaceutical aids).
[0166] The primary medium or carrier in a pharmaceutical composition may be either aqueous or non-aqueous. For example, suitable mediums or carriers may be water for injection, physiological saline solution, or artificial cerebrospinal fluid, which may optionally be supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary mediums. Other exemplary pharmaceutical compositions include Tris buffer at approximately pH 7.0–8.5, or acetate buffer at approximately pH 4.0–5.5, which may further contain sorbitol or a suitable substitute thereof. In one embodiment of this disclosure, a composition may be prepared for storage by mixing a selected composition having a desired degree of purity in the form of a lyophilized cake or aqueous solution with an optional formulation agent (Remington's Pharmaceutical Sciences, cited above). Furthermore, therapeutic compositions may be formulated as lyophilized products using appropriate excipients, such as sucrose. The optimal pharmaceutical composition will be determined by those skilled in the art, for example, depending on the intended route of administration, the delivery format, and the desired dosage.
[0167] When parenteral administration is intended, the therapeutic pharmaceutical composition may be in the form of a pyrogen-free, parenterally acceptable aqueous solution containing a desired polyspecific or bifunctional polyspecific antagonist molecule in a pharmaceutically acceptable medium. A particularly preferred medium for parenteral injection is sterile distilled water, in which the polypeptide is formulated as a sterile isotonic solution that can be properly stored. In various embodiments, a pharmaceutical formulation suitable for injectable administration may be formulated in an aqueous solution, preferably in a physiologically compatible buffer, such as Hanks' solution, Ringer's solution, or physiological buffered saline. The aqueous injection suspension may contain a substance that increases the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Additionally, the suspension of the active compound may be prepared as a suitable oily injection suspension. Optionally, the suspension may also contain a suitable stabilizer or agent to increase the solubility of the compound, which may allow for the preparation of a highly concentrated solution.
[0168] In various embodiments, therapeutic pharmaceutical compositions may be formulated for targeted delivery using colloidal dispersion systems. Colloidal dispersion systems include polymer complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Examples of lipids useful in liposome production include phosphatidyl compounds, e.g., phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Exemplary phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoylphosphatidylcholine. Liposome targeting is also possible, for example, based on organ specificity, cell specificity, and organelle specificity, which is known in the art.
[0169] In various embodiments, oral administration of pharmaceutical compositions is envisioned. Pharmaceutical compositions administered in this manner may be formulated with or without carriers conventionally used in the formulation of solid dosage forms, such as tablets and capsules. In solid dosage forms for oral administration (e.g., capsules, tablets, pills, sugar-coated tablets, powders, and granules), one or more therapeutic compounds of the present disclosure may be one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or the following: (1) fillers or bulking agents, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) wetting agents, such as glycerol; (4) disintegrants, such as (5) Dissolution retarders, e.g., paraffin; (6) Absorption enhancers, e.g., quaternary ammonium compounds; (7) Wetting agents, e.g., cetyl alcohol and glycerol monostearate; (8) Absorbents, e.g., kaolin and bentonite clay; (9) Lubricants, e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof; and (10) Colorants may be mixed with any of these. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain buffering agents. Similar types of solid compositions may also be used as fillers in soft and hard-filled gelatin capsules using high molecular weight polyethylene glycol, in addition to excipients such as lactose or milk sugar. Liquid dosing forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to the active ingredient, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed, peanut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan, as well as mixtures thereof. Besides inert diluents, the oral composition may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, colorants, fragrances, and preservatives.
[0170] In various embodiments, topical administration of the pharmaceutical composition to either the skin or mucous membranes is envisioned. Topical formulations may further include one or more of a variety of agents known to be effective as skin or stratum corneum permeability enhancers. Examples of these include 2-pyrrolidone, N-methyl-2-pyrrolidone, dimethylacetamide, dimethylformamide, propylene glycol, methyl or isopropyl alcohol, dimethyl sulfoxide, and azon. Additional agents may be included to make the formulation cosmetically acceptable. Examples of these include fats, waxes, oils, pigments, fragrances, preservatives, stabilizers, and surfactants. Keratinolants, such as those known to those skilled in the art, may also be included. Examples include salicylic acid and sulfur. Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any required preservatives, buffers, or propellants. The ointments, pastes, creams, and gels may contain, in addition to the compounds of this disclosure (e.g., polyspecific or bifunctional polyspecific antagonist molecules), excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, talc, and zinc oxide, or mixtures thereof.
[0171] Additional pharmaceutical compositions envisioned for use herein include formulations involving polypeptides in sustained or controlled delivery formulations. Various other sustained or controlled delivery means, such as liposome carriers, biodegradable microparticles or porous beads, and techniques for formulating depot injections are also known to those skilled in the art.
[0172] The effective dose of a therapeutically used pharmaceutical composition depends, for example, on the therapeutic context and purpose. Those skilled in the art will understand that the appropriate dosage level for a treatment will therefore vary in part depending on the molecule being delivered, the indication for which the polypeptide is used, the route of administration, and the patient's size (body weight, body surface or organ size) and condition (age and overall health). Thus, clinicians can titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect. Typical dosages may range from about 0.1 mg / kg to about 100 mg / kg or more, depending on the factors mentioned above. Polypeptide compositions may preferably be administered by intravenous injection or administration. Long-acting pharmaceutical compositions may be administered every 3-4 days, weekly, or bi-weekly, depending on the half-life and clearance rate of the particular formulation. The frequency of administration depends on the pharmacokinetic parameters of the polypeptide in the formulation used. Typically, the composition is administered until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as multiple doses (of the same or different concentrations / doses) over time, or as a series of infusions. Further refinement of the appropriate dosage is carried out as usual. The appropriate dosage may be confirmed through the use of appropriate dose-response data.
[0173] The route of administration of the pharmaceutical composition follows known methods, for example, by oral, intravenous, intraperitoneal, intracerebral (intraparum), intraventricular, intramuscular, intraocular, intraarterial, intraportal, intrafocal, intramedullary, intrathecal, intraventricular, percutaneous, subcutaneous, or intraperitoneal injection; otherwise, by intranasal, intraintestinal, topical, sublingual, urethral, transvaginal, or rectal means, by a continuous-release system, or by an implantable device. If desired, the composition may be administered continuously by bolus injection or infusion, or by an implantable device. Alternatively or additionally, the composition may be administered topically via implantation of a membrane, sponge, or other suitable material in which the desired molecule is absorbed or encapsulated. When an implantable device is used, the device may be implanted in any suitable tissue or organ, and the delivery of the desired molecule may be done by diffusion, time-release bolus, or continuous administration.
[0174] therapeutic use In another embodiment, the present disclosure provides methods for treating or preventing various complex disease conditions whose pathogenesis involves activation of the TGF-β / activin-mediated Smad2 / 3 signaling pathway.
[0175] In various embodiments, the novel polyspecific or bifunctional polyspecific antagonist molecules of the present invention are used to treat the following conditions: Hematological disorders: ineffective erythropoiesis, anemia, pancytopenia, myelodysplastic syndrome; Fibrotic diseases: non-alcoholic steatohepatitis / NASH, hepatic fibrosis, pulmonary fibrosis, renal fibrosis, polycystic kidney disease, cardiac fibrosis, muscular fibrosis, myelofibrosis, cutaneous fibrosis, and ocular fibrosis; Hematological malignancies: multiple myeloma, leukemia, and lymphoma; Solid cancers: melanoma, multiple myeloma, lung cancer, pancreatic cancer, colorectal cancer, liver cancer, stomach cancer, kidney cancer, bladder cancer, head and neck cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, testicular cancer, prostate cancer, and brain cancer; Metastases: bone metastases, lung metastases, liver metastases, brain metastases, and sarcomas; Checkpoint inhibitors For example, cancer treatment in combination with anti-PD1, anti-PDL1, and anti-CTL4 antibodies; neuromuscular diseases: muscular dystrophy, spinal muscular atrophy, spinal cord injury, stroke; pain: nociceptive pain, neuropathic pain; wasting disorders: sarcopenia, cancer cachexia, cardiac cachexia, renal cachexia, rheumatic cachexia, and anorexia nervosa; bone disorders: bone metastases, skeletal events in cancer, bone fragility, fractures, osteopenia, and osteoporosis; cardiovascular diseases: pulmonary hypertension, myocardial infarction, heart failure; metabolic disorders: insulin resistance, diabetic nephropathy, chronic kidney disease; inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease; infections: SARS-CoV, cytokine storm syndrome, sepsis; and trauma: including, but not limited to, burns.
[0176] This disclosure provides a method for treating cardiovascular disease in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or in a combination therapy regimen) of a pharmaceutically acceptable carrier containing a multispecific antagonist molecule of this disclosure, wherein such administration reduces inflammation and fibrosis of the vascular system, as well as of muscle, including smooth muscle, cardiac muscle, and skeletal muscle. In particular, the multispecific antagonist molecules of this disclosure are useful in treating heart failure, pulmonary hypertension, myocarditis, coronary artery disease, myocardial infarction, cardiac arrhythmias, cardiac valve disease, cardiomyopathy, pericardial disease, aortic disease, Marfan syndrome, and cardiac atrophy.
[0177] This disclosure provides a method for treating cardiac dysfunction or heart failure in a subject, comprising administering an effective amount of a multispecific antagonist molecule to the subject. Modulation may improve the cardiac function of the subject by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. Improvement in cardiac function may be assessed by echocardiography to measure cardiac pump function, focusing on 1) the volume of blood pumped and the efficiency of pumping, and 2) myocardial function, focusing on the strength of myocardial contraction.
[0178] This disclosure provides a method for treating a metabolic disorder in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or in a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the multispecific antagonist molecule of this disclosure is useful in treating metabolic disorders selected from obesity, dyslipidemia, diabetes mellitus, insulin resistance, sarcopenic obesity, steatosis, and metabolic syndrome, as well as diabetic myopathy, nephropathy, neuropathy, retinopathy, osteopenia, impaired glucose tolerance, hyperglycemia, and androgen depletion.
[0179] This disclosure provides a method for treating cancer cells, as well as cancer cell metastases, in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or in a combination therapy regimen) of a pharmaceutically acceptable polyspecific or bifunctional polyspecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier, wherein such administration inhibits the growth and / or proliferation of cancer cells. In particular, the polyspecific or bifunctional polyspecific antagonist molecules of this disclosure are useful in treating disorders characterized as cancer. Such disorders include, but are not limited to, solid tumors, such as cancers of the breast, airway, brain, genitals, gastrointestinal tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases, lymphoma, sarcoma, multiple myeloma, and leukemia. Examples of breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. Examples of airway cancers include, but are not limited to, small cell and non-small cell lung cancers, as well as bronchial adenomas and pulmonary pleuriblastomas. Examples of brain cancers include, but are not limited to, brainstem and hypothalamic (hypophthalmic) gliomas, cerebellar and cerebral astrocytomas, medulloblastomas, ependymomas, as well as neuroectoderm and pineal gland tumors. Tumors of the male reproductive organs include, but are not limited to, prostate and testicular cancers. Tumors of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancers, as well as uterine sarcomas. Tumors of the gastrointestinal tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, stomach, pancreatic, rectal, small intestine, and salivary gland cancers. Tumors of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, and urethral cancers. Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma. Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (hepatocellular carcinoma with or without fibrous lamellar variants), cholangiocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular cholangiocarcinoma. Skin cancer includes, but is not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell carcinoma, and non-melanoma skin cancer. Head and neck cancer includes, but is not limited to, nasopharyngeal cancer and lip cancer.Lymphoma includes, but is not limited to, AIDS-associated lymphoma, non-Hodgkin lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and central nervous system lymphoma. Sarcoma includes, but is not limited to, soft tissue sarcomas, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma. Leukemia includes, but is not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and hairy cell leukemia. In certain embodiments, cancer is cancer with high expression of TNF-α and TGF-β, such as pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer, melanoma, leukemia, lung cancer, prostate cancer, brain cancer, bladder cancer, and head and neck cancer.
[0180] This disclosure provides a method for treating chronic kidney disease (CKD) in a subject, comprising administering to the subject a therapeutically effective dose (as either monotherapy or a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier, wherein such administration attenuates loss of renal function, prevents muscle loss, or inhibits renal fibrosis. In particular, the multispecific antagonist molecule of this disclosure is useful in treating CKD, including interstitial fibrosis, renal failure, and henodialysis, as well as in treating protein-energy-wasting (PEW) associated with CKD. Modulation may improve the subject's CKD or PEW by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. Improvement in renal function can be assessed by measuring the protein / creatinine ratio (PCR) and glomerular filtration rate (GFR) in urine. Improvement in PEW can be assessed by measuring serum levels of albumin and inflammatory cytokines, rates of protein synthesis and degradation, body weight, muscle mass, physical activity, and nutritional outcomes.
[0181] This disclosure provides a method for treating an autoimmune disease in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or in a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the bifunctional antagonist molecule of this disclosure is useful in treating autoimmune disorders selected from multiple sclerosis, diabetes mellitus (type 1), glomerulonephritis, myasthenia gravis, psoriasis, systemic sclerosis and systemic lupus erythematosus, polymyositis, and primary biliary cirrhosis.
[0182] This disclosure provides a method for treating arthritis in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or as part of a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the bifunctional antagonist molecule of this disclosure is useful in treating arthritis selected from rheumatoid arthritis and osteoarthritis.
[0183] This disclosure provides a method for treating anorexia in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or as part of a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the bifunctional antagonist molecule of this disclosure is useful in treating anorexia selected from anorexia nervosa and anorexia-cachexia syndrome.
[0184] This disclosure provides a method for treating liver disease in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or as part of a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the multispecific antagonist molecule of this disclosure is useful in treating liver diseases selected from non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcoholic fatty liver disease, cirrhosis, hepatic failure, autoimmune hepatitis, and hepatocellular carcinoma.
[0185] This disclosure provides a method for performing organ or tissue transplantation in a subject, comprising administering to the subject a therapeutically effective dose (either as monotherapy or in a combination therapy regimen) of the multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In particular, the multispecific antagonist molecule of this disclosure is useful in transplantation procedures selected from organ transplantation of the heart, kidney, liver, lung, pancreas, intestine, and thymus, or tissue transplantation of bone, tendon, cornea, skin, heart valve, nerve, and vein.
[0186] This disclosure provides a method for treating anemia in a subject, comprising administering to the subject a therapeutically effective dose (as either monotherapy or a combination therapy regimen) of a multispecific antagonist molecule of this disclosure in a pharmaceutically acceptable carrier. In various embodiments, the anemia is selected from a variety of anemia disorders, including cancer-related anemia, chemotherapy-induced anemia, chronic kidney disease-related anemia, iron deficiency anemia, iron and hemochromatosis, thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndrome, pancytopenia, and bone marrow failure.
[0187] This disclosure provides a method for treating fibrosis in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention to a subject in need thereof. In one embodiment, the subject is a human subject. In various embodiments, the fibrosis is selected from pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis and cystic fibrosis), hepatic fibrosis (e.g., non-alcoholic steatohepatitis and cirrhosis), airway fibrosis (e.g., asthma), cardiac fibrosis (e.g., myocardial infarction, diastolic dysfunction or heart valve disease), renal fibrosis (e.g., interstitial fibrosis), myelofibrosis, idiopathic retroperitoneal fibrosis, nephrogenic fibrous skin disorders, intestinal fibrosis in inflammatory bowel disease (inducing Crohn's disease), keloids, scleroderma, systemic sclerosis, and arthral fibrosis.
[0188] This disclosure provides a method for treating pain in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention to a subject in need thereof. In one embodiment, the subject is a human subject. In various embodiments, the pain is selected from neuropathic pain, inflammatory pain, or cancer pain.
[0189] This disclosure provides a method for treating a bone disease in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of the present invention to a subject in need thereof. In one embodiment, the subject is a human subject. In various embodiments, the bone disease is selected from osteomalacia, osteoporosis, osteogenesis imperfecta, fibrodysplasia ossificans progressive, corticosteroid-induced osteopenia, fractures, and bone metastases.
[0190] This disclosure provides a method for inhibiting the loss of muscle mass and / or muscle function in a subject, comprising administering an effective amount of a multispecific antagonist molecule to the subject. The modulation may attenuate the loss of muscle mass and / or function in the subject by at least 5%, 10%, at least 25%, at least 50%, at least 75%, or at least 90%. The inhibition of muscle mass and function loss may be evaluated using imaging techniques and physical strength tests. Examples of imaging techniques for muscle mass evaluation include dual-energy X-ray absorptiometry (DEXA), magnetic resonance imaging (MRI), and computed tomography (CT). Examples of muscle function tests include grip strength tests, stair climbing tests, short physical performance batteries (SPPB), and 6-minute walk tests, as well as maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used to measure respiratory muscle strength.
[0191] The "therapeutic dose" refers to the amount of a therapeutic agent administered that alleviates one or more symptoms of the disorder being treated to some degree.
[0192] The effective therapeutic dose is IC 50The dose can first be estimated from the cell culture assay by determining the IC. 50 Formulas can be formulated in animal models to achieve the circulating plasma concentration range, including [specific parameters]. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by HPLC. The exact composition, route of administration, and dosage can be selected by individual physicians, taking into account the conditions of the subject.
[0193] Dosage regimens can be adjusted to provide the optimal desired response (e.g., therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses (multiple, repeated, or maintenance) may be administered over time, and the dose may be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. Formulating parenteral compositions in dosing unit forms is particularly advantageous for ease of administration and uniformity of dosage. When used herein, dosing unit forms refer to physically separate units suitable as unit doses for the mammalian subject being treated; each unit contains a predetermined amount of the active compound calculated to produce the desired therapeutic effect in relation to the required pharmaceutical carrier. The specifications for dosing unit forms in this disclosure are primarily governed by the unique characteristics of the antibody and the specific therapeutic or prophylactic effect to be achieved.
[0194] Therefore, those skilled in the art will understand, based on the disclosures provided herein, that doses and administration regimens are adjusted according to methods well known in the therapeutic field. That is, the maximum acceptable dose can be readily established, the effective dose that provides a detectable therapeutic benefit to the subject can also be determined, and the time requirements for administering each agent to provide a detectable therapeutic benefit to the subject can be similarly determined. Thus, while certain doses and administration regimens are illustrated herein, these examples are by no means limited to the doses and administration regimens that may be provided to the subject in practice of this disclosure.
[0195] It should be noted that the dosage values may vary with the type and severity of the condition to be alleviated, and may include one or more doses. It should be further understood that for any particular subject, a specific dosage regimen should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and that the dosage ranges described herein are illustrative and not intended to limit the scope or implementation of the claimed composition. Furthermore, dosage regimens using the compositions of this disclosure may be based on a variety of factors, including the type of disease, the subject's age, weight, sex, medical condition, severity of the condition, route of administration, and the specific antibody used. Therefore, dosage regimens can vary widely but can be routinely determined using standard methods. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamic parameters, which may include clinical effects, e.g., toxic effects and / or experimental values. Therefore, this disclosure includes dose escalation within a subject as determined by those skilled in the art. The determination of appropriate dosages and regimens is well known in the relevant art and will be understood to be attainable by those skilled in the art once the teachings disclosed herein are provided.
[0196] Exemplary, non-limiting daily dosing ranges for therapeutic or prophylactic effective doses of the polyspecific or bifunctional polyspecific antagonist molecules of this disclosure include 0.001–100 mg / kg, 0.001–90 mg / kg, 0.001–80 mg / kg, 0.001–70 mg / kg, 0.001–60 mg / kg, 0.001–50 mg / kg, and 0.001–4 0mg / kg, 0.001~30mg / kg, 0.001~20mg / kg, 0.001~10mg / kg, 0.001~5mg / kg, 0.001~4mg / kg, 0.00 1~3mg / kg, 0.001~2mg / kg, 0.001~1mg / kg, 0.010~50mg / kg, 0.010~40mg / kg, 0.010~30mg / kg, 0. 010~20mg / kg, 0.010~10mg / kg, 0.010~5mg / kg, 0.010~4mg / kg, 0.010~3mg / kg, 0.010~2mg / kg, 0.010~1mg / kg, 0.1~50mg / kg, 0.1~40mg / kg, 0.1~30mg / kg, 0.1~20mg / kg, 0.1~10mg / kg, 0.1~5m The dosage may be g / kg, 0.1-4 mg / kg, 0.1-3 mg / kg, 0.1-2 mg / kg, 0.1-1 mg / kg, 1-50 mg / kg, 1-40 mg / kg, 1-30 mg / kg, 1-20 mg / kg, 1-10 mg / kg, 1-5 mg / kg, 1-4 mg / kg, 1-3 mg / kg, 1-2 mg / kg, or 1-1 mg / kg body weight. It should be noted that the dosage values may vary with the type and severity of the condition to be alleviated. It should be further understood that for any particular subject, a specific dosage regimen should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the composition, and that the dosage ranges described herein are illustrative only and are not intended to limit the scope or implementation of the claimed composition.
[0197] In various embodiments, the total dose administered achieves plasma antibody concentrations within the following ranges, for example: approximately 1-1000 μg / ml, approximately 1-750 μg / ml, approximately 1-500 μg / ml, approximately 1-250 μg / ml, approximately 10-1000 μg / ml, approximately 10-750 μg / ml, approximately 10-500 μg / ml, approximately 10-250 μg / ml, approximately 20-1000 μg / ml, approximately 20-750 μg / ml, approximately 20-500 μg / ml, approximately 20-250 μg / ml, approximately 30-1000 μg / ml, approximately 30-750 μg / ml, approximately 30-500 μg / ml, and approximately 30-250 μg / ml.
[0198] The toxicity and therapeutic index of the pharmaceutical compositions disclosed herein are, for example, LD50. 50 (A lethal dose for 50% of the population) and ED 50 The therapeutically effective dose (the dose that is therapeutically effective in 50% of the population) can be determined by standard medical procedures in cell cultures or experimental animals. The dose ratio between the toxic dose and the therapeutically effective dose is the therapeutic index, and the therapeutic index is the ratio LD50. 50 / ED 50 It can be expressed as follows. Compositions exhibiting a large therapeutic index are generally preferred.
[0199] The frequency of administration of a pharmaceutical composition of a multispecific or bifunctional multispecific antagonist molecule depends on the nature of the therapy and the specific disease being treated. The subject may be treated at regular intervals, for example, weekly or monthly, until the desired therapeutic outcome is achieved. Exemplary dosing frequencies include, but are not limited to, once a week without breaks; once a week every other week; once every two weeks; once every three weeks; once a week for two weeks without breaks, then monthly; once a week for three weeks without breaks, then monthly; monthly; once every two months; once every three months; once every four months; once every five months; or once every six months; or annually.
[0200] Combination therapy When used herein, the terms “combined administration,” “administered in combination,” and “in combination with” referring to the multispecific or bifunctional multispecific antagonist molecules and one or more other therapeutic agents of the Disclosure are intended to mean, refer to, and include: simultaneous administration of such combination of the multispecific or bifunctional multispecific antagonist molecules and therapeutic agents of the Disclosure to a subject requiring treatment, wherein the components are formulated together to constitute a single dosage form that releases the components to the subject at substantially the same time; or substantially simultaneous administration of such combination of the multispecific or bifunctional multispecific antagonist molecules and therapeutic agents of the Disclosure to a subject requiring treatment, wherein the components are formulated separately from each other to constitute separate dosage forms that are ingested by the subject at substantially the same time. In cases where the components are released in such a manner; in cases where the components are formulated separately from each other to constitute separate dosing forms that are ingested by the subject over a continuous period of time with a significant time interval between each dosing, and the components are released to the subject over substantially different periods of time in such ingestion; and in cases where the components are formulated together to constitute a single dosing form that releases the components in a controlled manner, and the components are released to the subject over the same and / or different periods of time in parallel, sequentially, and / or overlapping, and each portion may be administered via the same or different routes.
[0201] In another embodiment, the Disclosure provides a method for treating cancer or cancer metastasis in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition of the Invention in combination with a second therapy selected from the group consisting of cytotoxic chemotherapy, immunotherapy, small molecule kinase inhibitor targeted therapy, surgery, radiotherapy, and stem cell transplantation. In various embodiments, the combination therapy may also include administering a therapeutically effective amount of immunotherapy to the subject, where the immunotherapy is: treatment using depletion antibodies against specific tumor antigens; treatment using antibody-drug conjugates; treatment using agonists, antagonists, or blocking antibodies against costimulatory or coinhibitory molecules (immune checkpoints), e.g., CTLA-4, PD-1, PD-L1, OX-40, CD137, TIGIT, GITR, LAG3, TIM-3, CD47, SIRPα, ICOS, and VISTA; treatment using bispecific T cell engaging antibodies (BiTE®), e.g., blinatumomab; and biological response modifiers, e.g., TNF family, IL-1, I Treatments involving the administration of L-4, IL-7, IL-12, IL-15, IL-17, IL-21, IL-22, GM-CSF, IFN-α, IFN-β and IFN-γ; treatments using therapeutic vaccines, e.g., cypleurol-T; treatments using dendritic cell vaccines or tumor antigen peptide vaccines; treatments using chimeric antigen receptor (CAR)-T cells; treatments using CAR-NK cells; treatments using tumor-infiltrating lymphocytes (TILs); treatments using adoptively transferred antitumor T cells (ex vivo proliferating and / or TCR transgenic); treatments using TALL-104 cells; and immunostimulants, e.g., Toll-like receptors (TLRs: TLR7, TLR8, and TLR 9) Treatments including, but not limited to, those using the agonist CpG and imiquimod; combination therapy provides increased effector cell killing of tumor cells, i.e., a synergistic effect exists between the multispecific antagonist molecule or the bifunctional multispecific antagonist molecule and immunotherapy when administered in combination.
[0202] In various embodiments, combination therapy involves simultaneously administering a composition of a multispecific or bifunctional multispecific antagonist molecule and a composition of a second agent, either in the same pharmaceutical composition or in separate pharmaceutical compositions. In various embodiments, the composition of the multispecific or bifunctional multispecific antagonist molecule and the composition of the second agent are administered sequentially, i.e., the composition of the multispecific or bifunctional multispecific antagonist molecule is administered either before or after the administration of the composition of the second agent.
[0203] In various embodiments, the administration of the composition of the polyspecific or bifunctional polyspecific antagonist molecule and the composition of the second agent occur simultaneously, i.e., the administration periods of the composition of the polyspecific or bifunctional polyspecific antagonist molecule and the composition of the second agent overlap with each other.
[0204] In various embodiments, the administration of the composition of the multispecific or bifunctional multispecific antagonist molecule and the composition of the second agent are asynchronous. For example, in various embodiments, the administration of the composition of the multispecific or bifunctional multispecific antagonist molecule is completed before the administration of the composition of the second agent. In various embodiments, the administration of the composition of the second agent is completed before the administration of the composition of the bifunctional antagonist molecule.
[0205] The following embodiments are provided for the purpose of better illustrating the present disclosure, but are not intended to limit its scope. [Examples]
[0206] Example 1 The polyspecific and / or bifunctional polyspecific antagonist molecules of this disclosure can be prepared according to recombinant DNA techniques well known to those skilled in the art. In these examples, the preparation of bifunctional antagonist molecules is generally described.
[0207] cDNAs encoding various novel polyspecific or bifunctional polyspecific antagonist polypeptides were generated via gene synthesis and subcloned into mammalian expression plasmids. CHO cells were transiently or stably transfected with mammalian expression plasmids encoding individual polyspecific or bifunctional polyspecific polypeptide antagonists. Transiently transfected CHO cells or stably transfected CHO pools were grown in high-density suspension cultures in a 32°C CO2 shaking incubator for 6–8 days. The culture medium was collected after passing through a 0.22 μm filter unit (Millipore Corporation, MA). Recombinantly expressed polyspecific or bifunctional polyspecific polypeptides were purified from the culture medium via protein A affinity chromatography using an AKTA PFLC system (GE Healthcare).
[0208] Example 2 The binding activity of individual polyspecific or bifunctional polyspecific antagonists to human ligands or target proteins was measured by biolayer interferometry (BLI) using Octet RED96 (ForteBIO, Pall Corporation, USA). Binding analysis was first performed by capturing polypeptide polyspecific or bifunctional polyspecific antagonists onto a biosensor. To measure the rates of association and dissociation, the biosensor containing the polypeptide antagonists was immersed for 10 minutes in wells containing different concentrations of specific ligands or target proteins (e.g., activin A, activin B, activin AB, myostatin, GDF-8, GDF-11, TGF-β1, TGF-β3, PD1, and CTLA4) diluted in 1x kinetic buffer, followed by 10–20 minutes of immersion in 1x kinetic buffer. The sensors, which had captured polypeptide antagonists, were also immersed in wells containing 1x kinetic buffer to enable single-reference subtraction to compensate for the innate dissociation of the captured polypeptide antagonists. Binding sensorgrams were collected using an 8-channel detection mode for the biosensor. Data were acquired and analyzed using ForteBIO Data acquisition software v11.1 (ForteBIO, Pall Corporation, USA).
[0209] The binding affinity of the multispecific antagonist molecules A115, A116, A117, and A118 was investigated using BLI analysis. As depicted in Table 10, the multispecific polypeptide antagonists A115, A116, A117, and A118 were able to selectively bind with high affinity to a subset of the TGF-β superfamily, including activin A, activin B, activin AB, GDF-8, GDF-11, TGF-β1, and TGF-β3. When the multispecific polypeptide antagonist A216, engineered in a different configuration than A116, was investigated for its ligand binding, the data demonstrated that A216 possessed a high binding affinity similar to that of A116. Therefore, multispecific polypeptide antagonists engineered in different configurations can achieve high affinity ligand binding. TIFF2023548399000015.tif109170
[0210] Furthermore, the ligand-binding affinities of the antibody-based multispecific antagonists A155 and A167 were investigated using BLI analysis. As shown in Table 11, A155 and A167 were able to bind to activin A, TGF-β1, and TGF-β3 with high affinity. TIFF2023548399000016.tif55170
[0211] Example 3 Smad2 / 3 Signaling Assay. Ligand signaling activity in cell culture was measured using the engineered luciferase reporter cell line C2C12-CAGA-luc that has the ability to sense Smad2 / 3 signaling. To measure the neutralizing activity of the multispecific antagonists, 2 nM of human activin A, activin B, activin AB, myostatin, GDF-11, TGF-β1, or TGF-β3 was preincubated with each individual antagonist at increasing concentrations of 0.00004 nM, 0.0004 nM, 0.004 nM, 0.04 nM, 0.4 nM, 4 nM, 40 nM, and 400 nM for 1 hour at room temperature, and the preincubated reaction mixture was then added to the C2C12-CAGA-luc reporter cell culture. After 5 hours of incubation in a 37 °C CO2 incubator, the luciferase activity of the reporter culture was measured by using LuminoSkan Ascent (Thermo Scientific). The IC 50 values were analyzed and plotted using Prism software (GraphPad Software).
[0212] As depicted in FIGS. 6-8, the bifunctional multispecific antagonists A115, A116, A117, and A118, A-119, and A-120 potently neutralize activin A and activin B (FIG. 6), TGF-β1 and TGF-β3 (FIG. 7), and GDF-8 and GDF-11 (FIG. 8) in cell-based assays.
[0213] Example 4 Elevated activin and TGF-β have been linked to cancer cell migration and metastasis. Both activin and TGF-β are highly upregulated in the tumor microenvironment, and the parallel upregulation of activin and TGF-β in the tumor microenvironment has been widely reported. To mimic the parallel upregulation of activin A and TGF-β1 in the tumor microenvironment, activin A and TGF-β1 were added together to A549 lung cancer cell cultures. Under this condition, the effects of the dual-specificity antagonist of activin and TGF-β, A116, on cancer cell migration were examined in a cell migration assay by comparing it with ActRIIA-Fc (activin inhibitor) and TGFRII-Fc (TGF-β inhibitor), respectively.
[0214] Cancer cell migration assay. To examine the effects of dual-specificity antagonists of activin and TGF-β on cancer cell migration, a cell monolayer scratch assay was performed using A549 human non-small cell lung cancer cells. A549 cancer cells were plated in multi-well plates and grown as a monolayer culture in DMEM supplemented with 10% fetal bovine serum (FBS) in a 37 °C CO2 incubator. When the cells reached 90% confluence, the cultures were scratched with a 200 μl pipette tip to create a wound gap on the cell monolayer across each well. The cultures were then switched to DMEM supplemented with 0.2% FBS with or without the addition of the following agents: 1) none (control), 2) activin A (50 ng / mL) + TGF-β1 (5 ng / mL), 3) activin A (50 ng / mL) + TGF-β1 (5 ng / mL) + ActRIIA-Fc (2.5 μg / mL), 4) activin A (50 ng / mL) + TGF-β1 (5 ng / mL) + TGFRII-Fc (2.5 μg / mL), and 5) activin A (50 ng / mL) + TGF-β1 (5 ng / mL) + A116 (2.5 μg / mL). Forty-eight hours after treatment, the cell cultures were photographed using an inverted microscope equipped with a digital camera.
[0215] Figure 10 depicts the effect of the multifunctional peptide antagonist A116 on the migration of A549 lung cancer cells. As shown in Panel A, the wound gap remained large in the untreated A549 control culture at 48 hours of incubation. In contrast, with combined activin A and TGF-β1 treatment, the wound gap was completely closed at 48 hours of incubation, indicating that activin A and TGF-β1 dramatically accelerate the migration of A549 lung cancer cells. Under the same conditions, inhibition of activin A by ActRIIA-Fc or inhibition of TGF-β1 by TGFRII-Fc did not prevent wound gap closure at 48 hours of incubation (Panels C and D), suggesting that inhibition of activin A or TGF-β1 alone is insufficient to prevent accelerated cancer cell migration when both activin A and TGF-β1 are elevated. However, in the presence of high levels of activin and TGF-β1, the addition of the multispecific antagonist A116 highly effectively prevented wound space narrowing in A549 cancer cell cultures, and the wound space size of cultures treated with A216 remained approximately the same as that of untreated control cultures (Panel E). These results demonstrate that the multispecific antagonist A116 can inhibit accelerated cancer cell migration mediated by activin A and TGF-β in parallel. The results suggest that the novel multispecific antagonists of activin and TGF-β disclosed herein may represent a promising new approach to treating cancer metastasis, and that these novel antagonists may more effectively prevent cancer cell migration and metastasis by simultaneously blocking elevated activin and TGF-β in the tumor microenvironment.
[0216] Example 5 The literature has reported that the expression levels of activin A and TGF-β are elevated in parallel in various types of malignancies, including lung cancer. To evaluate the effects of multispecific antagonists of activin and TGF-β on the tumorigenic potential of cancer cells, colony formation assays were performed in human A549 non-small cell lung cancer cells. To mimic the elevated activin and TGF-β in the tumor microenvironment, exogenous activin A and TGF-β1 were added together to the cell culture medium in A549 lung cancer cell cultures, and the effect of the multispecific polypeptide antagonist A116 was examined in colony formation assays compared to ActRIIA-Fc and TGFRII-Fc, respectively.
[0217] Cancer cell colony formation assay. To investigate the effects of activin and TGF-β multispecific antagonists on the tumorigenic potential of cancer cells, a colony formation assay was performed in A549 human lung cancer cell cultures. A549 lung cancer cells were plated in 6-well plates at a density of approximately 500 cells / well in DMEM supplemented with 0.2% FBS and incubated for 14 days in the presence of the following agents: 1) Activin A (50 ng / mL) + TGF-β1 (5 ng / mL), 2) Activin A (50 ng / mL) + TGF-β1 (5 ng / mL) + ActRIIA-Fc (2.5 μg / mL), 3) Activin A (50 ng / mL) and TGF-β1 (5 ng / mL) + TGFRII-Fc (2.5 μg / mL), and 4) Activin A (50 ng / mL) and TGF-β1 (5 ng / mL) + A116 (2.5 μg / mL). The culture medium was changed twice a week, and colony density was counted on day 14. Colony formation was defined as >50 cells per colony. Representative microscopic images were taken with a digital camera.
[0218] Figure 11 depicts the effect of A116 on A549 colony formation in the presence of exogenously added activin A and TGF-β1. As shown in panels A–D, the density of A549 colonies was lower in cultures treated with ActRIIA-Fc, TGFRII-Fc, or A116, suggesting that inhibition of activin or TGF-β has an inhibitory effect on colony formation. However, the inhibitory effect of A116 on A549 colony formation was significantly higher compared to the inhibitory effect of ActRIIA-Fc or TGFRII-Fc, indicating that parallel inhibition of activin A and TGF-β1 by A116 is more effective in suppressing colony formation by A549 cancer cells (Figure 12). The enhanced antitumorogenic effect of A116 suggests that the novel multispecific antagonists of activin and TGF-β disclosed herein represent a promising new approach for cancer treatment.
[0219] Example 6 TGF-β is a major driver of tissue fibrosis, and TGF-β-mediated Smad2 / 3 signaling plays a central role in the pathogenesis of fibrosis. Like TGF-β, activin B also mediates Smad2 / 3 signaling, playing an essential role in the pathogenesis of fibrosis, in addition to activin A. TGF-β and activin A are upregulated in parallel in fibrotic disease tissues, and elevated TGF-β and activin A have been shown to act synergistically to promote disease progression by stimulating collagen overproduction and extracellular matrix deposition. Due to the parallel involvement of TGF-β and activin in fibrosis, dual targeting of elevated TGF-β and activin may improve treatment efficacy. Therefore, it is important to search for novel antagonists with the ability to simultaneously inhibit TGF-β and activin in order to more effectively combat fibrotic diseases.
[0220] In this example, A116, a novel polypeptide-based multispecific antagonist capable of simultaneously neutralizing TGF-β and activin, was evaluated for its ability to attenuate bleomycin-induced pulmonary fibrosis in mice, compared to activin-neutralizing protein, ActRIIA-Fc, and TGF-β-neutralizing protein, TGFRII-Fc, respectively.
[0221] A mouse model study of bleomycin-induced pulmonary fibrosis. All animal-involved procedures were approved by the Animal Experimentation Committee. Eight-week-old male C57BL / 6 mice were purchased from Jackson Laboratories. Mice were maintained in a 12-hour light / dark cycle and given free access to water and laboratory rodent feed. Mice were acclimatized for one week before treatment. Bleomycin (Sigma) was dissolved in sterile 0.9% saline and administered as a single dose of 0.5 mg / kg per animal. Control animals were given saline alone. All animals received intratracheal injection (IT) of either bleomycin or saline on day 0. Mice were randomly assigned to one of the following groups: (1) IT saline (control); (2) IT bleomycin (bleomycin); (3) IT bleomycin with ActRIIA-Fc treatment (bleomycin + ActRIIA-Fc-Fc); (4) IT bleomycin with TGFRII-Fc (bleomycin + TGFRII-Fc); (5) IT bleomycin with A1116 treatment (bleomycin + A116). Starting on day 2, ActRIIA-Fc, TGFRII-Fc, and A-120 were administered to each mouse group once a week via SC administration at doses of 5-10 mg / kg normalized by the molecular weight of each agent. After 2 weeks of treatment, the animals were sacrificed, right lung tissue was collected in cassettes and fixed in neutral buffered formalin. For histological evaluation, the samples were dehydrated in graded ethanol series, clarified in xylene, and embedded in paraffin. Sections 4–6 μm thick were cut and stained with hematoxylin and eosin (H&E), Masson's trichrome (TM), and HRP-linked anti-alpha-SMA antibodies. Fibrous lung injury was histologically evaluated using the Ashcroft scoring system (Hubner et al. 2008. PMID: 18476815; DOI: 10.2144 / 000112729). Ashcroft scores were analyzed at 10X magnification.
[0222] Figure 13 shows histological images of H&E-stained lung sections and Ashcraft scores of lung sections in a mouse model of bleomycin-induced pulmonary fibrosis. Data indicate that dual inhibition of TGF-β and activin with A116 significantly reduced bleomycin-induced pulmonary fibrosis, while the activin inhibitor ActRIIA-Fc or the TGF-β blocker TGFRII-Fc moderately inhibited bleomycin-induced pulmonary fibrosis. Analysis of Ashcraft scores revealed that A116 treatment resulted in a greater reduction of pulmonary fibrosis compared to ActRIIA-Fc or TGFRII-Fc treatment.
[0223] Figure 14 depicts histological images of Masson trichrome-stained lung sections from mice with bleomycin-induced pulmonary fibrosis and bar graphs representing a quantitative analysis of collagen deposition area in the lung sections. The data demonstrate that A116 attenuated collagen deposition more effectively than ActRIIA-Fc or TGFRII-Fc in the bleomycin-induced pulmonary fibrosis model.
[0224] Figure 15 shows histological images of immunochemical staining for α-SMA, a marker of fibrosis, in lung sections from control and bleomycin-treated mice. Lung sections were immunostained with a primary anti-α-SMA antibody in combination with an HRP-labeled secondary antibody. The results indicate that A116 was more effective than ActRIIA-Fc or TGFRII-Fc in preventing the induction of α-SMA in the lungs of bleomycin-treated mice.
[0225] In summary, experimental data from mice with bleomycin-induced pulmonary fibrosis demonstrated that A116 is more effective than ActRIIA-Fc or TGFRII-Fc in preventing fibrosis. The enhanced anti-fibrotic effect observed with dual inhibition of activin and TGF-β by A116 in the bleomycin mouse model suggests that A116, along with other novel, multispecific antagonists of activin and TGF-β from the present invention, could represent a more effective therapeutic approach to combat fibrotic diseases.
[0226] All articles and methods disclosed and claimed in this application can be manufactured and performed without excessive experimentation in light of the present invention. Although the articles and methods of the present invention are described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations can be applied to the articles and methods without deviating from the spirit and scope of the present invention. All such variations and equivalents, whether existing or subsequently developed, which are apparent to those skilled in the art, are considered to be within the spirit and scope of the present invention as defined by the appended claims. All patents, patent applications, and publications referenced herein indicate the level of those skilled in the art in the field relating to the present invention. All patents, patent applications, and publications are incorporated herein by reference in whole for all purposes, and to the same extent that each individual publication is specifically and individually indicated to be incorporated by reference in whole for any and all purposes. The present invention, preferably described exemplary herein, may be carried out in the absence of any elements not specifically disclosed herein. Therefore, although the present invention is particularly disclosed by preferred embodiments and optional features, it should be understood that modifications and variations of the concepts disclosed herein may be taken by those skilled in the art, and that such modifications and variations are considered to fall within the scope of the present invention as defined by the appended claims.
[0227] Sequence List The nucleic acid and amino acid sequences listed in the attached sequence listing are shown using standard abbreviations for nucleotide bases and three-letter codes for amino acids, as defined in 37 CFR 1.822. Sequence IDs 1-9 are amino acid sequences of various activins or activin-related ligands. Sequence IDs 10 and 14 are amino acid sequences of the heavy chains of various antibodies that specifically bind to activin or activin-related ligands. Sequence IDs 11 and 15 are amino acid sequences of the light chains of various antibodies that specifically bind to activin or activin-related ligands. Sequence IDs 12 and 16 are amino acid sequences of the heavy chain variable regions of various antibodies that specifically bind to activin or activin-related ligands. Sequence IDs 13 and 17 are amino acid sequences of the light chain variable regions of various antibodies that specifically bind to activin or activin-related ligands. Sequence IDs 18-21 are amino acid sequences of various TGF-β ligands. Sequence ID 22 is the amino acid sequence of the heavy chain of an antibody that specifically binds to TGF-β ligand. Sequence ID 23 is the amino acid sequence of the light chain of an antibody that specifically binds to TGF-β ligand. Sequence ID 24 is the amino acid sequence of the heavy chain variable region of an antibody that specifically binds to a TGF-β ligand. Sequence ID 25 is the amino acid sequence of the light chain variable region of an antibody that specifically binds to a TGF-β ligand. Sequence IDs 26, 30, 38, and 42 are the amino acid sequences of the heavy chains of various antibodies that specifically bind to PD-1 ligands. Sequence IDs 27, 31, 39, and 43 are the amino acid sequences of the light chains of various antibodies that specifically bind to PD-1 ligands. Sequence IDs 28, 32, 40, and 44 are amino acid sequences of the heavy chain variable regions of various antibodies that specifically bind to PD-1 ligands. Sequence IDs 29, 33, 41, and 45 are amino acid sequences of the light chain variable regions of various antibodies that specifically bind to PD-1 ligands. Sequence ID 34 is the amino acid sequence of the heavy chain of an antibody that specifically binds to the CTLA-4 ligand. Sequence ID 35 is the amino acid sequence of the light chain of an antibody that specifically binds to the CTLA-4 ligand. Sequence ID 36 is the amino acid sequence of the heavy chain variable region of an antibody that specifically binds to the CTLA-4 ligand. Sequence ID 37 is the amino acid sequence of the light chain variable region of an antibody that specifically binds to a CTLA-4 ligand. SEQ ID NO: 46 and 50 are the amino acid sequences of the heavy chains of various antibodies that specifically bind to the PD-L1 ligand. SEQ ID NO: 47 and 51 are the amino acid sequences of the light chains of various antibodies that specifically bind to the PD-L1 ligand. SEQ ID NO: 48 and 52 are the amino acid sequences of the heavy chain variable regions of various antibodies that specifically bind to the PD-L1 ligand. SEQ ID NO: 49 and 53 are the amino acid sequences of the light chain variable regions of various antibodies that specifically bind to the PD-L1 ligand. SEQ ID NO: 54 - 71 are the amino acid sequences of various bispecific antagonist molecules that specifically bind to activin or activin-related ligands and specifically bind to the TGF-β ligand. SEQ ID NO: 72 - 84 are the amino acid sequences of the heavy chains of bispecific antagonist molecules that specifically bind to activin or activin-related ligands or the TGF-β ligand. SEQ ID NO: 85 - 120 are the amino acid sequences of the heavy chains of bifunctional bispecific antagonist molecules that specifically bind to either activin or activin-related ligands, the TGF-β ligand, and the PD-1 ligand or the CTLA-4 ligand or the PD-L1 ligand. SEQ ID NO: 121 is the amino acid sequence of a bispecific antagonist molecule that specifically binds to activin or activin-related ligands and specifically binds to the TGF-β ligand. SEQ ID NO: 122 is the amino acid sequence of the heavy chain of a bispecific antagonist molecule that specifically binds to activin or activin-related ligands or the TGF-β ligand. SEQ ID NO: 123 is the amino acid sequence of the light chain of a bispecific antagonist molecule that specifically binds to activin or activin-related ligands or the TGF-β ligand. SEQ ID NO: 124 - 143 are the amino acid sequences of various peptide linker sequences. Sequence Listing Human ActRIIA-ECD ETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPP(Sequence ID 1) Human ActRIIB-ECD ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT(Sequence ID 2) Human follistatin 315 GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW(Sequence ID 3) Human follistatin ΔHBS (modified follistatin) GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGQSCVVDQTGSPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW (Sequence ID 4) Human follistatin 288 GNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCN (Sequence ID 5) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCEGDQDKRLHCYASWRNSSGTIELVKKGCWLDDINCYDRQECVATKENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT(Sequence ID 6) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCYGDKDKRRHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT(Sequence ID 7) Modified Human ActRIIB ECD ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWDDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPT(Sequence ID 8) Modified Human ActRIIA ECD GAILGRSETQECLFYNANWELERTNQTGVEPCEGEKDKRLHCYATWRNISGSIEIVKKGCWLDDFNCYDRTDCVETEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS(Sequence ID 9) Anti-activin antibody heavy chain amino acid sequence QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWIIPYNGNTNSAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARDRDYGVNYDAFDIWGQG TMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNVYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 10) Light chain amino acid sequence of anti-activin A antibody SYEVTQAPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 11) Amino acid sequence of the variable region of the heavy chain of anti-activin A antibody QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGLSWVRQAPGQGLEWMGWIIPYNGNTNSAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYFCARDRDYGVNYDAFDIWGQGTMVTVSS(Sequence ID 12) Amino acid sequence of the variable region of the light chain of anti-activin A antibody SYEVTQAPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVL(Sequence ID 13) Anti-activin A antibody heavy chain amino acid sequence QVQLQESGPGLVKPSETLSLTTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDI WGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP PCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 14) Light chain amino acid sequence of anti-activin A antibody EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 15) Amino acid sequence of the variable region of the heavy chain of anti-activin A antibody QVQLQESGPGLVKPSETLSLTCTVSGGSFSSHFWSWIRQPPGKGLEWIGYILYTGGTSFNPSLKSRVSMSVGTSKNQFSLKLSSVTAADTAVYYCARARSGITFTGIIVPGSFDIWGQGTMVTVSS (Sequence ID 16) Amino acid sequence of the variable region of the light chain of anti-activin A antibody EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (Sequence ID 17) Human TGF-β receptor II isoform 1 MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSD ECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEE YASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYM APEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK (Sequence No. 18) Human TGF-β receptor II-ECD isoform 1 (TGF-β RIIB-ECD) TIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence ID 19) Human TGF-β receptor II isoform 2 (Sequence ID 20) Human TGF-β receptor II-ECD isoform 2 (TGF-β RIIA-ECD) TIPPHVQKSDVEMEAQKDEIICPSCNRTAHPLRHINNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 21) Anti-TGF-β antibody heavy chain amino acid sequence QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP SCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(Sequence ID 22) Light chain amino acid sequence of anti-TGF-β antibody ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 23) Amino acid sequence of the variable region of the heavy chain of anti-TGF-β antibody QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS (Sequence ID 24) Amino acid sequence of the variable region of the light chain of anti-TGF-β antibody ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK (Sequence ID 25) Anti-PD1 antibody heavy chain amino acid sequence QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQG TTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 26) Light chain amino acid sequence of anti-PD1 antibody EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 27) Amino acid sequence of the variable region of the heavy chain of anti-PD1 antibody QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS(Sequence ID 28) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIK (Sequence ID 29) Anti-PD1 antibody heavy chain amino acid sequence QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVS SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPA PEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (Sequence ID 30) Light chain amino acid sequence of anti-PD1 antibody EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 31) Amino acid sequence of the variable region of the heavy chain of anti-PD1 antibody QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS (Sequence ID 32) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK(Sequence ID 33) Anti-CTLA-4 antibody heavy chain amino acid sequence QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 34) Light chain amino acid sequence of anti-CTLA-4 antibody EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 35) Amino acid sequence of the variable region of the heavy chain of anti-CTLA-4 antibody QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS (Sequence No. 36) Amino acid sequence of the variable region of the light chain of anti-CTLA-4 antibody EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK (Sequence ID 37) Anti-PD1 antibody heavy chain amino acid sequence EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYW GQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRV ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALH NHYTQKSLSLSLGK(Sequence ID 38) Light chain amino acid sequence of anti-PD1 antibody DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 39) Amino acid sequence of the variable region of the heavy chain of anti-PD1 antibody EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS (Sequence No. 40) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR(Sequence ID 41) Anti-PD1 antibody heavy chain amino acid sequence EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(Sequence ID 42) Light chain amino acid sequence of anti-PD1 antibody QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS(Sequence ID 43) Amino acid sequence of the variable region of the heavy chain of anti-PD1 antibody EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS (Sequence ID 44) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL(Sequence ID 45) Anti-PD-L1 antibody heavy chain amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 46) Light chain amino acid sequence of anti-PD-L1 antibody DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 47) Amino acid sequence of the variable region of the heavy chain of anti-PD-L1 antibody EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (Sequence No. 48) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK (Sequence ID 49) Anti-PD-L1 antibody heavy chain amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT CPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 50) Light chain amino acid sequence of anti-PD-L1 antibody EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 51) Amino acid sequence of the variable region of the heavy chain of anti-PD-L1 antibody EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS(Sequence ID 52) Amino acid sequence of the variable region of the light chain of anti-PD1 antibody EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK (Sequence ID 53) A115 amino acid sequence ETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPPGGGGSGGGGSGGGGSEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 54) A116 amino acid sequence (Sequence ID 55) A140 amino acid sequence ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPTGGGGSGGGGSGGGGSEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 56) A141 amino acid sequence (Sequence ID 57) A142 amino acid sequence (Sequence ID 58) A143 amino acid sequence (Sequence ID 59) A117 amino acid sequence (Sequence ID 60) A118 amino acid sequence (Sequence ID 61) A144 amino acid sequence (Sequence ID 62) A145 amino acid sequence (Sequence No. 63) A146 amino acid sequence ETRECIYYNANWELERTNQSGLERCEGDQDKRLHCYASWRNSSGTIELVKKGCWLDDINCYDRQECVATKENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPTGGGGSGGGGSGGGSEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 64) A147 amino acid sequence (Sequence ID 65) A148 amino acid sequence ETRECIYYNANWELERTNQSGLERCYGDKDKRRHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPTGGGGSGGGGSGGGGSEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 66) A149 amino acid sequence (Sequence ID 67) A150 amino acid sequence ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWDDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTGGGGSGGGGSGGGGSEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence No. 68) A151 amino acid sequence (Sequence ID 69) A152 amino acid sequence GAILGRSETQECLFYNANWELERTNQTGVEPCEGEKDKRLHCYATWRNISGSIEIVKKGCWLDDFNCYDRTDCVETEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGGSGGGGGSGGGGSEPKSC DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD(Sequence ID 70) A153 amino acid sequence (Sequence ID 71) A154 heavy chain amino acid sequence (Sequence ID 72) A155 heavy chain amino acid sequence (Sequence ID 73) A156 heavy chain amino acid sequence (Sequence ID 74) A157 heavy chain amino acid sequence (Sequence ID 75) A158 heavy chain amino acid sequence (Sequence ID 76) A159 heavy chain amino acid sequence (Sequence ID 77) A160 heavy chain amino acid sequence (Sequence ID 78) A161 heavy chain amino acid sequence (Sequence ID 79) A162 heavy chain amino acid sequence (Sequence ID 80) A163 heavy chain amino acid sequence (Sequence No. 81) A164 heavy chain amino acid sequence (Sequence No. 82) A165 heavy chain amino acid sequence (Sequence No. 83) A166 heavy chain amino acid sequence (Sequence No. 84) A169 heavy chain amino acid sequence (Sequence ID 85) A170 heavy chain amino acid sequence (Sequence No. 86) A171 heavy chain amino acid sequence (Sequence ID 87) A172 heavy chain amino acid sequence (Sequence No. 88) A173 heavy chain amino acid sequence (Sequence ID 89) A174 heavy chain amino acid sequence (Sequence ID 90) A175 heavy chain amino acid sequence (Sequence ID 91) A176 heavy chain amino acid sequence (Sequence ID 92) A177 heavy chain amino acid sequence (Sequence ID 93) A178 heavy chain amino acid sequence (Sequence ID 94) A179 heavy chain amino acid sequence (Sequence ID 95) A180 heavy chain amino acid sequence (Sequence ID 96) A181 heavy chain amino acid sequence (Sequence ID 97) A182 heavy chain amino acid sequence (Sequence ID 98) A183 heavy chain amino acid sequence (Sequence ID 99) A184 heavy chain amino acid sequence (Sequence ID 100) A185 heavy chain amino acid sequence (Sequence ID 101) A186 heavy chain amino acid sequence (Sequence ID 102) A187 heavy chain amino acid sequence (Sequence ID 103) A188 heavy chain amino acid sequence (Sequence ID 104) A189 heavy chain amino acid sequence (Sequence ID 105) A190 heavy chain amino acid sequence (Sequence ID 106) A191 heavy chain amino acid sequence (Sequence ID 107) A192 heavy chain amino acid sequence (Sequence ID 108) A193 heavy chain amino acid sequence (Sequence ID 109) A194 heavy chain amino acid sequence (Sequence ID 110) A195 heavy chain amino acid sequence (Sequence ID 111) A196 heavy chain amino acid sequence (Sequence ID 112) A197 heavy chain amino acid sequence (Sequence ID 113) A198 heavy chain amino acid sequence (Sequence ID 114) A199 heavy chain amino acid sequence (Sequence ID 115) A200 heavy chain amino acid sequence (Sequence ID 116) A201 heavy chain amino acid sequence (Sequence ID 117) A202 heavy chain amino acid sequence (Sequence No. 118) A203 heavy chain amino acid sequence (Sequence ID 119) A204 heavy chain amino acid sequence (Sequence ID 120) A216 amino acid sequence (Sequence ID 121) A167 heavy chain amino acid sequence (Sequence ID 122) A167 Light chain amino acid sequence SYEVTQAPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTAVFGGGTKLTVLGGGGSGGGGSGGGGSETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH KVYACEVTHQGLSSPVTKSFNRGECA (Sequence ID 123) Peptide linker sequence GGGSGGGSGGGS (SEQ ID NO: 124) Peptide linker sequence GGGS (SEQ ID NO: 125) Peptide linker sequence GSSGGSGGSGGSG (SEQ ID NO: 126) Peptide linker sequence GSSGT (SEQ ID NO: 127) Peptide linker sequence GGGGSGGGGSGGGS (Sequence ID 128) Peptide linker sequence AEAAAKEAAAKEAAAKA (SEQ ID NO: 129) Peptide linker sequence GGGGSGGGGSGGGGSGGGGS (Sequence ID 130) Peptide linker sequence GGGSGGGS (SEQ ID NO: 131) Peptide linker sequence GSGST (SEQ ID NO: 132) Peptide linker sequence GGSS (SEQ ID NO: 133) Peptide linker sequence GGGGS (SEQ ID NO: 134) Peptide linker sequence GGSG (SEQ ID NO: 135) Peptide linker sequence SGGG (SEQ ID NO: 136) Peptide linker sequence GSGS (SEQ ID NO: 137) Peptide linker sequence GSGSGS (SEQ ID NO: 138) Peptide linker sequence GSGSGSGS (SEQ ID NO: 139) Peptide linker sequence GSGSGSGSGS (SEQ ID NO: 140) Peptide linker sequence GSGSGSGSGSGS (SEQ ID NO: 141) Peptide linker sequence GGGGSGGGGS (Sequence ID 142) Peptide linker sequence GGGGSGGGGSGGGGS (Sequence ID 143)
Claims
1. An isolated multispecific antagonist comprising a first antigen-binding molecule that specifically binds to activin or an activin-related ligand and a second antigen-binding molecule that specifically binds to a TGF-β ligand, wherein the multispecific antagonist molecule simultaneously neutralizes activin signaling and TGF-β signaling in a potent manner.
2. 2. The isolated multispecific antagonist of claim 1, wherein the first antigen-binding molecule specifically binds to an activin or activin-related ligand selected from the group consisting of activins or activin-related ligands comprising the amino acid sequences set forth in SEQ ID NOs: 1-9, and the second antigen-binding molecule specifically binds to a TGF-β ligand selected from the group consisting of TGF-β family ligands comprising the amino acid sequences set forth in SEQ ID NOs: 18-21.
3. The first antigen-binding polypeptide that specifically binds to activin or an activin-related ligand ("activin-binding polypeptide") is selected from the group consisting of anti-activin antibodies (including anti-activin A and anti-activin B antibodies), fragments of anti-activin antibodies, wild-type activin receptor type 2A (ActRIIA) or activin receptor type 2B (ActRIIB) extracellular domains (ECDs), modified ActRIIA and ActRIIB extracellular domains, wild-type and modified native activin binding proteins, such as follistatin, follistatin-like proteins and propeptides, and phage display-derived polypeptides targeting activin or an activin-related ligand; and the second antigen-binding polypeptide that specifically binds to a TGF-β ligand ("TGF-β binding polypeptide") is selected from the group consisting of anti-TGF-β antibodies, fragments of anti-TGF-β antibodies, wild-type TGF-β 3. The isolated multispecific antagonist of any one of claims 1 to 2, selected from the group consisting of type 2 receptor (including TGFβRIIA and TGFβRIIB) extracellular domains (ECDs), modified TGFβRIIA and TGFβRIIB extracellular domains, and phage display-derived antagonist polypeptides targeting TGF-β ligands.
4. 4. The isolated multispecific antagonist molecule of any one of claims 1 to 3, wherein the activin binding polypeptide is selected from the group of polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 1-17, and the TGF-β binding polypeptide is selected from the group of polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 18-25.
5. The isolated multispecific antagonist molecule of any one of claims 1 to 4, wherein the activin-binding polypeptide comprises an isolated anti-activin antibody, or an antigen-binding fragment thereof, and the TGF-β-binding polypeptide comprises an isolated anti-TGF-β antibody, or an antigen-binding fragment thereof.
6. 6. The isolated multispecific antagonist molecule of claim 5, wherein the isolated anti-activin antibody or antigen-binding fragment thereof and the isolated anti-TGF-β antibody or antigen-binding fragment thereof are selected from the group consisting of monoclonal Abs (mAbs), polyclonal Abs, Ab fragments (e.g., Fab, Fab', F(ab')2, Fv, Fc, etc.), chimeric Abs, miniAbs or domain Abs (dAbs), bispecific Abs, bispecific Abs, heteroconjugate Abs, single chain Abs (SCAs), single chain variable fragments (ScFvs), humanized Abs, fully human Abs, and any other modified configuration of an immunoglobulin (Ig) molecule that contains an antigen recognition site of the required specificity.
7. The isolated multispecific antagonist molecule of any one of claims 5 to 6, wherein said isolated antibody or antigen-binding fragment thereof is selected from the group consisting of fully human, humanized and chimeric antibodies.
8. 8. The isolated multispecific antagonist molecule of any one of claims 5 to 7, wherein the activin binding polypeptide is an isolated antibody selected from the group consisting of an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 10; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO: 11; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 10 and a light chain amino acid sequence set forth in SEQ ID NO: 11; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 12; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO: 13; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 12 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 13; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 14; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO: 15; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 14 and a light chain variable region ... variable region amino acid sequence set forth in SEQ ID NO: 16; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO: 17; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 16 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
17.
9. 9. The isolated multispecific antagonist molecule of any one of claims 5 to 8, wherein said TGF-beta binding polypeptide is an isolated antibody selected from the group consisting of an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:22; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:23; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:22 and a light chain amino acid sequence set forth in SEQ ID NO:23; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:24; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:25; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:24 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
25.
10. 3. The isolated multispecific antagonist molecule of any one of claims 1 to 2, comprising an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOs: 54-71.
11. 3. The isolated multispecific antagonist molecule of any one of claims 1 to 2, wherein said multispecific antagonist polypeptide is a polypeptide molecule comprising a heavy chain selected from the group consisting of heavy chains comprising the amino acid sequences set forth in SEQ ID NOs: 72-84 and a light chain selected from the group consisting of light chains comprising the amino acid sequences set forth in SEQ ID NOs: 11, 13, 15, 17, 19, 21, 23 and 25.
12. 1. An isolated bifunctional, multispecific antagonist polypeptide comprising a first antigen-binding polypeptide that specifically binds to an activin ligand or an activin-related ligand (an "activin-binding polypeptide"), a second antigen-binding polypeptide that specifically binds to a TGF-β ligand (a "TGF-β binding polypeptide"), and a third antigen-binding polypeptide that specifically binds to either a T cell immune checkpoint PD-1 ligand, a PD-L1 ligand, or a CTLA-4 ligand (a "PD-1 / PD-L1 / CTLA-4 binding polypeptide"), wherein said bifunctional, multispecific antagonist molecule simultaneously inhibits TGF-β, activin, and the T cell immune checkpoint.
13. The bifunctional, multispecific antagonist molecule comprises a third antigen-binding polypeptide ("PD-1 binding polypeptide") that specifically binds to a PD-1 ligand; the PD-1 binding polypeptide is an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:26; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:27; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:26 and a light chain amino acid sequence set forth in SEQ ID NO:27; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:28; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:29; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:28 and a light chain variable region amino acid sequence set forth in SEQ ID NO:29; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:30; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:31; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:30 and ...2; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:
33. an antibody comprising a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:32 and a light chain variable region amino acid sequence as set forth in SEQ ID NO:33; an antibody comprising a heavy chain amino acid sequence as set forth in SEQ ID NO:38; an antibody comprising a light chain amino acid sequence as set forth in SEQ ID NO:39; an antibody comprising a heavy chain amino acid sequence as set forth in SEQ ID NO:38 and ... variable region amino acid sequence as set forth in SEQ ID NO:40; an antibody comprising a light chain variable region amino acid sequence as set forth in SEQ ID NO:41; an antibody comprising a heavy chain variable region amino acid sequence as set forth in SEQ ID NO:40 and a light chain variable region amino acid sequence as set forth in SEQ ID NO:41; an antibody comprising a heavy chain amino acid sequence as set forth in SEQ ID NO:42; an antibody comprising a light chain amino acid sequence as set forth in SEQ ID NO:43; an antibody comprising a heavy chain amino acid sequence as set forth in SEQ ID NO:42 and a light chain amino acid sequence as set forth in SEQ ID NO:43; an antibody comprising a heavy chain amino acid sequence as set forth in SEQ ID NO:44; an antibody comprising a light chain variable region amino acid sequence as set forth in SEQ ID NO:45;and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:44 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
45.
14. 13. The isolated bifunctional, multispecific antagonist molecule of claim 12, wherein said bifunctional, multispecific antagonist molecule comprises a third antigen-binding polypeptide that specifically binds to a CTLA-4 ligand ("CTLA-4 binding polypeptide"); said CTLA-4 binding polypeptide is an isolated antibody selected from the group consisting of: an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:34; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:35; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:34 and a light chain amino acid sequence set forth in SEQ ID NO:35; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:36; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:37; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:36 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
37.
15. The bifunctional, multispecific antagonist molecule comprises a third antigen-binding polypeptide that specifically binds to a PD-L1 ligand ("PD-L1 binding polypeptide"); the PD-L1 binding polypeptide is an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:46; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:47; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:46 and a light chain amino acid sequence set forth in SEQ ID NO:47; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:48; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:49; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:48 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
49.
13. The isolated bifunctional multispecific antagonist molecule of claim 12, which is an isolated antibody selected from the group consisting of an antibody comprising a light chain variable region amino acid sequence; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:50; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:51; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:50 and a light chain amino acid sequence set forth in SEQ ID NO:51; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:52; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:53; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:52 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
53.
16. 13. The isolated bifunctional, multispecific antagonist molecule of claim 12, wherein the bifunctional, multispecific molecule is selected from the group consisting of a bifunctional, multispecific antagonist molecule comprising a heavy chain selected from heavy chains comprising the amino acid sequences set forth in SEQ ID NOs: 85-120 and a light chain selected from light chains comprising the amino acid sequences set forth in SEQ ID NOs: 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51 and 53.
17. 17. The isolated bifunctional, multispecific antagonist molecule of claim 16, wherein the bifunctional, multispecific molecule is selected from the group consisting of a bifunctional, multispecific antagonist molecule comprising a heavy chain selected from those comprising the amino acid sequence set forth in SEQ ID NOs:85-102 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:
27.
18. 17. The isolated bifunctional, multispecific antagonist molecule of claim 16, wherein the bifunctional, multispecific molecule is selected from the group consisting of a bifunctional, multispecific antagonist molecule comprising a heavy chain selected from those comprising the amino acid sequence set forth in SEQ ID NOs: 103-120 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:
35.
19. A pharmaceutical composition comprising a therapeutically effective amount of a multispecific or bifunctional multispecific antagonist molecule according to any one of claims 1 to 18 in admixture with a pharma- ceutically acceptable carrier.
20. 20. The pharmaceutical composition of claim 19 for treating or preventing a disease state whose pathogenesis involves activation of both the TNF-α-mediated NF-κB signaling pathway and the activin-mediated Smad2 / 3 signaling pathway.
21. 21. The pharmaceutical composition of claim 20, wherein the disease state is selected from the group consisting of blood disorders, ineffective erythropoiesis, anemia, pancytopenia, myelodysplastic syndrome; fibrotic diseases: NASH, liver fibrosis, pulmonary fibrosis, kidney fibrosis, polycystic kidney disease, cardiac fibrosis, muscle fibrosis, bone marrow fibrosis, skin fibrosis, eye fibrosis, multiple myeloma, acute myeloid leukemia, melanoma, muscular dystrophy, spinal muscular atrophy, spinal cord injury, stroke, nociceptive pain, neuropathic pain, sarcopenia, cancer cachexia, anorexia nervosa, bone metastasis, bone fragility, fractures, osteopenia, osteoporosis, pulmonary hypertension, myocardial infarction, heart failure, insulin resistance, diabetic nephropathy, chronic kidney disease, rheumatoid arthritis, inflammatory bowel disease, SARS-CoV, cytokine storm syndrome, sepsis, and burn injury.
22. 20. The pharmaceutical composition according to claim 19 for treating or preventing cancer, wherein the cancer is selected from the group consisting of melanoma, multiple myeloma, lung cancer, pancreatic cancer, colorectal cancer, liver cancer, gastric cancer, kidney cancer, bladder cancer, head and neck cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, testicular cancer, prostate cancer and brain cancer.
23. A combination pharmaceutical for treating or preventing cancer, comprising: (i) a pharmaceutical composition according to claim 22; and (ii) an immune checkpoint inhibitor selected from the group consisting of anti-PD1, anti-PDL1, and anti-CTL4 antibodies; A combination medicine comprising:
24. An isolated nucleic acid molecule comprising a polynucleotide encoding a multispecific or bifunctional multispecific antagonist molecule according to any one of claims 1 to 18.
25. A recombinant vector comprising the nucleic acid molecule of claim 24.
26. A host cell comprising the recombinant vector of claim 25.
27. 20. A method for producing a multispecific or bifunctional multispecific antagonist molecule according to any one of claims 1 to 18, comprising the steps of a) transforming a host cell with a vector comprising a polynucleotide encoding said multispecific or bifunctional multispecific antagonist molecule, b) culturing said host cell under conditions suitable for expression of said multispecific or bifunctional multispecific antagonist molecule, and c) recovering said multispecific or bifunctional multispecific antagonist molecule from the culture.
